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Abstract 
Persistent corpus luteum (PCL) is one cause of infertility in mares. However, its nature is 
poorly understood. Furthermore, role of oxytocin during luteolysis is not clear. A series of 
experiments were conducted (1) to characterize PCL and to compare PCL with interovulatory-
intervals (IOIs) and (2) to evaluate the role of oxytocin during luteolysis. The induction of PCL 
was also attempted using a PGF2α secretion inhibitor. Oxytocin was used to induce luteolysis. 
Progesterone (P4) concentration decreased in IOI and PCL until Day 14 postovulation and then 
diverged, whereas PGFM concentration did not differ between groups. Transient P4 
depressions were observed during PCL. Before the end of luteolysis P4 concentration was less 
in PCL than IOI. Inhibition of PGF2α secretion caused a 1-day increase in the length of the 
luteal phase. Oxytocin caused a P4 decrease within 8-hours and a PGFM increase within 1-
hour after infusion and induced partial luteolysis.  
 
 
Key-words: Mare, Persistent corpus luteum, PGFM, Progesterone, Oxytocin. 
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Controlo da luteólise na égua 
Resumo 
O corpo lúteo persistente (PCL) é uma causa de infertilidade em éguas, no entanto a sua origem 
não é conhecida. Além disso, o papel da oxitocina na luteólise na égua não está claro. Foram 
realizados estudos para (1) caracterizar o PCL e comparar o PCL com intervalos-entre-
ovulações fisiológicos (IOI) e (2) determinar o papel da oxitocina na luteólise. A indução do 
PCL foi tentada através da inibição da secreção de PGF2α.  A oxitocina foi utilizada para 
induzir a luteólise. A progesterona (P4) diminuiu em éguas com IOI e PCL até ao dia 14 pós-
ovulação divergindo entre grupos posteriormente; a PGFM não diferiu entre grupos. Foram 
observadas diminuições transitórias de P4 na presença de PCL. Antes da luteólise a P4 era 
menor em éguas com PCL comparado com IOI. A inibição da secreção de PGF2α aumentou 
em 1 dia a duração da fase lútea. A oxitocina diminuiu a P4 em 8 horas e aumentou a PGFM 
em 1 hora após o início da infusão, causando luteólise parcial. 
 
Palavras chave: Égua, Corpo lúteo persistente, PGFM, Progesterona, Oxitocina. 
 
  
vii 
 
 
 
 
 
 
 
 
 
 
 
 
“Nature hides its secrets well.” 
O. J. Ginther 
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Preamble 
The estrous cycle of the mare has been subject of study for almost half a century. The 
fact that mares are a seasonal specie represents a challenge for the study of the physiological 
estrous cycle because of its short ovulatory season. From mid-summer until fall the 
characteristics of the estrous cycle begin to change which can lead researchers into erroneous 
conclusions about the reproductive physiology of the mare. Although numerous reports can be 
found on different subjects of the estrous cycle of the mare, this specie still holds and insists in 
keeping its secrets from us.  
The objectives of this thesis document were many fold. Firstly, we aimed to determine 
the role of oxytocin (OT) during luteolysis in mares, testing the hypothesis that luteolysis can 
be induced through the administration of OT. Of particular importance to this topic our 
objectives were (1) to determine a dose and method of administration of OT that will stimulate 
a PGFM pulse similar to a spontaneous pulse and (2) to study the role of OT in luteolysis. 
In some reports [1], it has been hypothesized that the failure of secretion of 
prostaglandin-F2α (PGF2α) at the time of expected luteolysis may be the cause of idiopathic 
persistent corpus luteum (PCL). Therefore, our second objective was to attempt the induction 
of the formation of the PCL through the inhibition of PGF2α secretion using a cyclooxygenase 
inhibitor administered at the time of expected luteolysis. Our third and last objective, was the 
characterization and description of the hormonal and ovarian changes during the spontaneous 
development of an idiopathic PCL from Day 12 until Day 22 (during the time of expected 
luteolysis that failed to occur) and during the maintenance of the idiopathic PCL (normalized 
to the end of luteolysis and ovulation at the end of an IOI and PCL).  
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1. Literature review 
1.1. Introduction 
 
The estrous cycle, or more precisely the interovulatory interval, begins at ovulation 
usually associated with estrus and ends at the ensuing ovulation associated with the next estrus. 
The mean length of an interovulatory interval is typically 22 or 24 days in horses or ponies, 
respectively. The estrous cycle or interovulatory interval is characterized behaviorally by 
diestrus (12 to 16 days) and estrus (5 to 9 days) or, physiologically, by luteal phase and 
follicular phases, respectively [2,3]. In this thesis document, attention will only be given to 
physiological characteristics of the interovulatory interval and not to the behavioral 
characteristics, since the latter can be misleading and usually associated with a large variation 
among individuals. In addition, the literature review presented herein will focus on the 
physiological events of the estrous cycle of the mare (follicular and luteal phase).  
 
1.2.1. Follicular phase 
 
a) The wave phenomenon 
 
In the domestic species the follicular development occurs in waves [2]. A major 
follicular wave in mares is defined as a number of several follicles that initially grow in 
synchrony but eventually dissociate or diverge in diameter [2,4]. Dissociation is characterized 
by preferential growth of one, occasionally two, members of the wave [2]. 
Waves are classified as major (divergence of follicles of a wave into dominant and 
subordinate follicles) and minor (no divergence) [4]. The largest follicle after divergence is 
named of dominant follicle, and those that regress after divergence are named of subordinate 
21 
 
 
follicles. The dominant follicle grows to a large diameter (e.g., > 30 mm), and this characteristic 
has also been used to define a major wave [2,4]. A minor follicular wave is characterized by 
the failure of the largest follicle to reach a large size and the apparent absence of dissociation 
and dominance. The terms secondary and primary waves have also been used for the equine 
estrous cycle. A secondary wave is a major wave that emerges during late estrus or early 
diestrus and its dominant follicle becomes anovulatory or terminates in a diestrous or secondary 
ovulation [4]. The development of a secondary follicular wave occurs in approximately 25% 
of the estrous cycles [5]. A primary wave is a major wave that originates during diestrus and 
gives origin to a dominant follicle that terminates in the primary ovulation (ovulation associated 
with estrus at the end of the interovulatory interval) [4]. 
 
b) Emergence 
 
Emergence of follicular waves refers to the earliest ultrasonic detection of follicles 
compatible with retrospective tracking and is represented in mares by diameters of 6 mm [6]. 
Emergence of the primary wave occurs in mean on Day 7.4 (Day 0 = ovulation; range from 
Day 3 to Day 14) [4]. Length of the interovulatory interval is positively correlated with the day 
of emergence of the primary wave. That is, early or late emergence of a wave is associated with 
shorter or longer interovulatory intervals, respectively [4]. Emergence of each wave is 
temporally associated with an FSH surge for both the major and minor waves in mares. The 
FSH surge reaches a peak or a plateau when the largest follicle reaches about 13 mm [7]. The 
FSH concentrations then decline [6]. In mares, the future dominant follicle emerges 1 day 
earlier than the future largest subordinate follicle [7]. 
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c) Acquisition of dominance / Deviation 
  
After emergence, the follicles of a wave enter a common-growth phase involving 
reported means of 7 to 11 follicles [7]. Usually, in mares, only one of the available follicles 
develops into the dominant follicle, and this phenomenon is known as folliclular selection. 
Follicle selection or deviation occurs at the end of the common-growth phase and is 
characterized by continued growth of the largest follicle to become the dominant follicle and a 
reduction or cessation of growth by the remaining follicles to become subordinate follicles 
[6,8]. The beginning of observed deviation in the diameter profiles of individual follicles occurs 
at the ultrasound examination preceding the first examination with an apparent change in 
diameter differences between the two largest follicles [9]. Mean diameter observed at the 
beginning of deviation in mares is 22.5 mm  with deviation beginning a mean of 6.2 days after 
emergence of a 6 mm follicle [6,7]. Between emergence and deviation, the growth rate of the 
two largest follicles seem parallel in about 50% of individual waves [7]. 
  The follicle that first reached 20 mm (with daily examinations) became the dominant 
follicle in 93% of 29 waves. This diameter occurred on average at the examination before the 
beginning of deviation [8]. In adition, on average, the future dominant follicle reached 6 mm 
before the future largest subordinate follicle and maintained a mean diameter advantage of 3 
mm until the beginning of deviation [7]. The difference in diameter between the two largest 
follicles at beginning of deviation is postulated to allow the largest follicle to establish 
dominance before the second largest follicle can reach a similar diameter [9]. The difference 
in diameter between the two largest follicles indicates that the smaller follicle must be inhibited 
in < 1 day (equivalent to a difference of 3 mm) [6]. The deviation mechanism must prevent the 
continued growth of the future subordinate follicles because they, as well as the future 
dominant follicle, are capable of dominance as indicated by studies involving ablation of 
specific follicles [6,10]. The deviation in diameter is likely preceded by biochemical or 
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functional deviation. In this regard, echotextural changes were detected in the wall of the largest 
follicle on the day before the beginning of diameter deviation in mares [11]. 
The main pituitary hormone in mares involved in the stimulation and regulation of 
follicle development is FSH [12]. A close two-way functional relationship between FSH and 
the follicles has been proposed to be an integral component of the deviation mechanism [8]. 
The depression of FSH concentration could be the critical event in deviation if the FSH is 
depressed below the quantities required by the smaller follicles, but not the largest follicle. The 
changes in FSH concentrations and follicle development are closely related [6]. The FSH surge 
that stimulates emergence of a wave begins to decline when the largest follicle is about 13 mm 
[6]. The interval from the beginning of the FSH decline to the beginning of deviation is about 
3 days. After the beginning of deviation, the concentration of FSH continue to decline reaching 
a nadir 2 or 3 days after deviation [6,13]. Follicular growth for about 2 days after emergence is 
independent of FSH. However, during the decline in the wave-stimulating FSH surge and 
before deviation, growth of follicle is dependent on FSH [13]. During the interval from the 
beginning of the FSH decline until the beginning of deviation, multiple follicles contribute to 
the FSH decline [8]. Nevertheless, FSH is needed to maintain follicular viability even after the 
FSH peak, that is, the declining FSH concentrations is required for continued follicle growth 
[13]. The FSH:follicle relationship changes from multiple to single-follicle at the beginning of 
deviation and has been demonstrated by ablating only the largest follicle, only the smaller 
follicle, or none of the follicles when the largest follicle reached ≥ 20 mm (expected day of 
deviation) [10]. The decline in FSH concentrations of the wave-stimulating  FSH surge 
continued for several days after ablation in the groups with no ablation or only the smaller 
follicle ablated. In the group with only the largest follicle ablated, the FSH and diameter of the 
smaller follicle increased within a day [10]. The continued decrease in FSH at the expected 
beginning of deviation can be attributed to the largest follicle, with no indication that the 
smaller follicle is involved [6]. Therefore, by the time of beginning of deviation, the future 
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dominant follicle develops the ability to suppress circulating FSH to below the concentration 
required by other follicles and the ability to utilize the low FSH concentrations in its further 
growth and development [6]. It has been proposed that regression of the smaller follicles 
involved a direct effect of follicle inhibitors secreted by the larger follicle, but the evidence is 
not convincing [14]. 
Inhibin, has been shown to be the FSH inhibitor during the early development of a 
follicular wave and is produced by the growing follicles of a follicular wave [12,15]. During 
the estrous cycle, in mares, peripheral concentration of total inhibin increase at the time FSH 
concentrations are declining, having a known negative feedback effect on FSH secretion 
[12,16,17]. Inhibin concentrations increase with follicle growth [18], but do not reach 
circulating concentrations that are sufficient to initiate a decline in the wave-stimulating FSH 
surge until the largest follicle reaches 12 or 13 mm [19,20]. An FSH-suppressing activity of 
equine follicular fluid has been demonstrated by an increase in FSH concentrations after 
ablation of follicles and is attributable to the removal of FSH-suppressing factors of follicle 
origin [6]. In adition, administration of an inhibin antiserum increased plasma FSH 
concentrations and increased the number of large follicles and ovulations [6]. The first 2 days 
of the FSH decrease are caused by inhibin, based on the positive relationship between the 
number of experimentally retained follicles and the extent of the increase in circulating total 
inhibin concentrations and the corresponding decrease in FSH. Near the expected day of 
deviation, total inhibin remained at elevated concentrations and likely contributed to the 
continuing FSH decline [8]. In this regard, treatment with serum containing inhibin antibodies 
on the day the largest follicle was 20 mm resulted in an increase in the number of 30 mm 
follicles [21,22]. After deviation, inhibin continues to be a FSH suppressant in mares [8]. 
  In mares, an increase in estradiol (E2) occurred in the follicular fluid [23], and 
echogenic changes characteristic of estrogen stimulation occurred in the wall of the future 
dominant follicle the day before the beginning of deviation [11]. The beginning of increased 
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local availability of E2 approximately coincides with the beginning of deviation. Reported 
autocrine and paracrine activities of E2 in the granulosa cells include enhancing aromatase 
enzyme activity, promoting expression of LH receptors, and enhancing the sensitivity to FSH 
and LH [8]. The production of E2 by the follicle at deviation has been shown to be dependent 
on gonadotropins [24]. The increased E2 produced by the developing dominant follicle near 
the beginning of deviation may be attributed to the transient elevation in LH concentrations 
and the increased expression of LH receptors by the granulosa cells [8]. Direct LH-induced 
secretion of E2 within the granulosa apparently has not been demonstrated in horses [25]. 
However, E2 does not begin to increase in the circulation until 1 or 2 days before the beginning 
of deviation in mares [19,23]. Thus, on a temporal basis, increased E2 apparently does not 
contribute to the FSH decline until the day before deviation. Ablation of the largest follicle at 
the expected beginning of deviation prevented the continuing E2 increase and resulted in 
associated FSH increase [10]. However, an FSH increase does not occur when only the second 
largest follicle is ablated [8]. Both E2 and inhibins are lost upon ablation of the largest follicle 
and a decrease in either or both could account for the resulting increase in FSH [8]. Inhibin 
from the wave of growing follicles apparently is the principal, if not the only, systemic FSH 
supressant during most of the common-growth phase. Circulating E2 concentrations increase 
near the beginning of deviation, and it appears that both inhibin and E2 contribute to the 
subsequent continuation of the FSH decline [8]. 
  Elevated LH concentrations were temporally associated with deviation and often were 
represented by a distinct part of the prolonged ovulatory LH surge in this species [7]. The 
granulosa cells of the future dominant follicle acquire LH receptors just before the beginning 
of deviation, providing a pathway for a functional LH effect of the early portion of the transient 
LH elevation [8]. Detectable amounts of LH receptors are present in granulosa cells of all 
follicles more than 5 mm in diameter in the mare and LH receptor content in granulosa cells 
increases with follicular diameter [18,26] being greater when the follicles are 20-24 mm than 
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15-19 mm [18], but a differential change in LH receptor content in granulosa cells of the future 
dominant versus subordinate follicles at the beginning of deviation has not been reported. 
Experimental reduction of LH concentrations decreased the diameter of the dominant follicle 
beginning 1 or 2 days after the beginning of deviation in mares [27,28]. A study with acyline 
induced gonadotropins supression and with administration of reFSH, reLH, or both showed 
that follicle diameters are dependent only on FSH during the first 48 hours after the beginning 
of deviation, with no aditional dependence on LH [24]. In adition, the reduced LH did not affect 
the second-largest follicle. Nevertheless, the onset of deviation was not delayed by the 
reduction of LH, but the post-deviation growth of the largest follicle was reduced [27]. The 
transient elevation in LH at deviation stimulates the IGF system, as well as the steroid system. 
At the beginning of deviation, the largest follicle is able to utilize the low concentrations of 
FSH, presumably enhanced by local effects of E2 and IGF-1. The second largest follicle has 
not developed to a similar extent and therefore cannot withstand the low FSH concentrations. 
Thereby, deviation is established before the second-largest follicle can develop to a stage that 
would allow it to assume the biochemical characteristics of a future dominant follicle [8].  
Before the beginning of deviation, differential concentration changes occur between the 
future dominant and subordinate follicle in E2, free insulin-like growth factor (IGF)-1, activin-
A, and inhibin-A [29,30]. The IGF-1 system seems to be the most critical among these factors 
for the initiation of deviation in mares. In experimental deviation, an increase in IGF-1 occurs 
before deviation, whereas E2, activin-A, and inhibin-A concentrations increase after deviation 
[12,30]. Acyline-treated mares were given reFSH, reLH, or both, and in the groups that were 
not given FSH replacement, the IGF-1 concentrations were lower in both the dominant and 
second largest follicles and the lower IGF-1 was assotiated with retardation of follicular 
growth. The temporal availability of IGF-1 as an enabling factor in deviation in mares was also 
supported by the greater concentration of free IGF-1 in the dominant follicle than in the second 
largest follicle at 48 hours after the expected beginning of deviation [24]. In adition, injection 
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of recombinant human IGF-1 into the second largest follicle at the expected beginning of 
deviation induced an increased incidence of dominance in the treated follicle [31,32] and 
injection of IGF binding proteins-3 (IGF antagonist) into the dominant follicle caused the 
regression of the dominant follicle and the subordinate follicle to become dominant [33]. 
Furthermore, the injection of recombinant human IGF-1 into the dominant follicle at the 
expected beginning of deviation maintained follicular growth in mares treated with acyline 
[34]. These findings lead to the conclusion that gonadotropins are needed for increased 
follicular fluid concentrations of free IGF-1 at the beginning of deviation in the mare, and the 
increase in intrafollicular free IGF-1 in the future dominant follicle is FSH dependent [24,34]. 
 
d) Follicular growth, periovulatory period and ovulation 
 
After deviation, the ovulatory follicle grows at a rate of 3 mm/day, reaching 35 mm 4 
days before ovulation or at the beginning of the preovulatory period. The growth rate continues 
until 2 days before ovulation when it reaches a mean preovulatory plateau of 41 mm [35]. 
The E2 and LH periovulatory surges begin approximately 10 days before the 
periovulatory period or near the end of luteolysis and a day or two before follicle deviation as 
mentioned previously [35,36]. Estradiol from the dominant follicle forms a surge in the plasma 
that reaches a peak two days before ovulation and then recedes. The LH concentrations in the 
ovulatory surge increase slowly and then more rapidly, with the transition between the slow 
and rapid increases occurring at the peak of the E2 surge. The enhanced output of LH reaches 
maximum 1 day after ovulation [35,36]. The change in rate of LH output during the surge in 
mares is attributable to a negative effect of E2 on LH throughout the LH surge [37]. A negative 
effect of the follicles [15] and specifically E2 [37] on LH has been demonstrated by follicle 
ablations and treatments with E2. The decrease in E2 and the reduction or cessation in growth 
of the preovulatory follicle beginning 2 days before ovulation are attributable to the 
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development of a reciprocal negative effect of LH on follicular E2 production when LH reaches 
a critical concentration. This conclusion is based on temporal relationships and on the E2 
decrease and reduction in follicle expansion beginning immediately after human chorionic 
gonadotropin treatment [38]. The initial rapid decrease in E2 from 2 days before to 1 day after 
ovulation is attributable to the negative effect of the rapidly increasing LH on E2, and the 
slower decrease after 1 day postovulation is attributable to the diminishing negative effect of 
the decreasing LH [39]. 
One to three surges in FSH concentrations occur during the luteal phase. The first surge 
begins just before ovulation when E2 is decreasing, and the peak of the last surge occurs when 
the largest follicle of the resulting ovulatory follicular wave is approximately 13 mm. 
Concentrations of FSH reach a nadir between the last surge of the estrous cycle and the first 
surge that will peak during the next cycle. The nadir occurs concomitantly with the 
preovulatory E2 peak. The occurrences of surges at different times and variation in the number 
of surges among mares account for the plateau in the mean FSH profile [35]. A negative effect 
of E2 on FSH accounts for the periovulatory E2/FSH temporal relationships; the negative effect 
has been demonstrated by the administration of E2 [20].  
A slight but significant increase in circulating progesterone (P4) occurs with 
consistency among mares on the day of detection of ovulation or a collapsed follicle. The LH 
decrease after the peak of the LH surge on day 1 is related to a negative effect of the 
postovulatory increase in P4. The negative effect of P4 on LH is indicated by the temporal 
relationships at the beginning and end of the luteal phase [36] and by a demonstrated negative 
effect of exogenous P4 on LH [27]. 
There is indication that considerable amounts of follicular fluid with high 
concentrations of hormones passes through the fimbrae of the oviduct into the peritoneal cavity 
at ovulation [5]. The hormones are absorbed from the peritoneal cavity and alter circulating 
concentrations of E2 and inhibin, which in turn alter concentrations of LH and FSH. A 
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preovulatory collection of fluid external to the ovary in the infundibular area has been detected 
by transrectal ultrasonic imaging [40,41]. As ovulation approaches, a bulge at the apex of the 
follicle can be detected at the ovulation fossa by ultrasonic imaging [41]. The follicular fluid 
enters the infundibular fluid during follicle evacuation at ovulation. Most of the follicular fluid 
passes into the abdomen, based on continuous ultrasonic imaging in mares [40]. 
The gradual preovulatory mean increase in each gonadotropin is temporarily disrupted 
at ovulation. Concentrations of LH and FSH increased significantly between 1 and 0.5 days 
before ovulation and 0.5 and 1 days after ovulation but not between 0.5 days before and 0.5 
days after ovulation. Concentrations of E2 decreased significantly between 1 and 0.5 days 
before ovulation and between the day of ovulation and 0.5 days after, but the decrease between 
0.5 days before ovulation and the day of ovulation was not significant [5,42]. The transient 
disruption in LH increase can be attributed to release of the E2 content of the follicular fluid 
into the peritoneal cavity, followed by absorption into the circulatory system [5,42]. A distinct 
spike in circulating immunoreactive (ir)-inhibin also occurs on the day of ovulation in mares 
[17]. It has been shown that inhibins increased immediately after ovulation and returned to 
basal concentrations in 12 hours. Sampling of peritoneal fluid showed inhibin-A concentrations 
that were 300 times greater immediately after ovulation than at other stages of estrus [43]. The 
spike in (ir)-inhibin concentrations in association with evacuation of the follicle at ovulation 
only partly accounts for the depicted transient suspension in the FSH increase from 0.5 days 
before to 0.5 days after ovulation [17]. In addition, a negative effect of E2 on FSH has been 
demonstrated by treatment with E2 [20]. The synergistic effect of E2 and inhibin from the 
follicular fluid that entered the peritoneal cavity more completely accounts for the transient 
suppression of the incline in FSH. The E2 content of the discharged follicular fluid on the day 
of ovulation [5] is adequate for disrupting the LH surge [37] and contributing to disruption of 
the FSH increase. 
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Ovulation is readily detected ultrasonically by the disappearance of a large follicle that 
was present at a recent previous examination [2]. 
 
1.2.2. Luteal phase 
 
a) Corpus luteum 
 
The corpus luteum (CL) is a transient endocrine gland involved in establishment and 
maintenance of pregnancy due to production of P4 and has a critical role in the estrous cycle 
periodicity [44]. The CL goes through a developmental, maintenance and regressive stages [2], 
and forms at the site of ovulation, developing from cells that remain in the follicle following 
ovulation but is eventually composed of multiple, distinctive cell types including steroidogenic 
cells (small and large luteal cells) and non-steroidogenic cells (endothelial cells, pericytes, 
fibrocytes, and immune cells) [45]. The luteal phase has a mean length of 14 days. 
After ovulation there is an immediate increase in P4 concentrations, starting on the 
ovulation day (Day 0) and reaches a maximum on Day 8. After Day 8, concentrations of P4 
decrease gradually until the beginning of luteolysis. The period between Day 8 and 14 is 
designated as preluteolytic period. The area of the corpus luteum reaches a maximum on Day 
4 and progressively decreases thereafter until Day 19. During preluteolysis the rate of decline 
in plasma P4 and area of CL are not different. The gradual decline in P4 concentrations during 
the preluteolytic period is temporally related to a gradual decline in LH concentrations from 
the ovulatory LH surge. The concomitant gradual decline in both P4 and luteal area seems 
attributable to a decreasing positive effect of LH on the CL [46]. 
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b) Corpus hemorragicum 
 
After ovulation, 68% of the luteal glands develop a large, fluid-filled, central area. The 
central area was attributable to blood [47], and the structure was designated by corpus 
hemorragicum. The central area develops gradually. It increases in area for the first 52 hours 
reaching a maximum at 72 hours. Echogenic lines within the central area were first detected, 
on average, 44 hours after follicle evacuation. The echogenic lines within the central area are 
attributable to clotting and fibrinization of the contents. Fibrin-like material within the blood 
clot is echogenic, so images of corpora lutea with this morphology had an echogenic network 
interspersed within the anechoic area [48]. The development of a central fluid area did not alter 
circulating P4 concentrations or the length of the interovulatory interval [2]. 
 
c) Luteolysis 
 
In the absence of a viable embryo, functional and structural regression of the CL occurs, 
event named luteolysis. A chronology of research findings in luteolysis in the mare for the past 
40 years has been reported [49]. Luteolysis is divided in three stages: preluteolysis, luteolysis, 
and postluteolysis. Preluteolysis occurs before the beginning of regression of the corpus luteum 
(defined as Days 8–14). Luteolysis is the period during regression of the corpus luteum until 
P4 has decreased to < 1 ng/mL. The period after luteolysis when concentrations are < 1 ng/mL 
is termed postluteolysis. Luteal transition refers to the hour at the end of preluteolysis and 
beginning of luteolysis, and is based on P4 determinations every hour [50]. The transitional 
hour is selected subjectively by inspection of the P4 profile for each animal and is based on the 
beginning of a progressive decrease in P4 in the hourly blood samples [51]. In the mare, 
luteolysis begins on average 14 days after ovulation or 9 days before the next ovulation, and it 
lasts approximately 23 hours, based in hourly blood sampling [50,52]. In many species, 
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including mares, CL regression is due to multiple pulses of prostaglandin F2α (PGF2α) 
secreted in a pulsatile way by the nonpregnant uterus [53]. Concentrations of PGF2α in the 
systemic circulation are usually assessed by measuring its metabolite, 15-keto-13,14-dihydro-
prostaglandin F2α (PGFM), owing to the short half-life of PGF2α [54,55]. Luteal regression 
involves secretion of PGF2α in several sequential pulses during the length of the luteolytic 
period (two to four pulses) [52,56]. The peak concentration does not differ between a 
preluteolytic and the transitional pulse (~ 45 pg/mL), but the peak concentrations increase 
progressively between the first luteolytic pulse (~ 78 pg/mL) and the second luteolystic pulse 
(~ 193 pg/mL) to the postluteolytic pulse (~ 305 pg/mL) [52]. The base of the PGFM 
concentrations is maintained throughout the three periods, but mechanisms exist for increasing 
the prominence of the pulses during luteolysis and postluteolysis. Contributing factors in this 
regard may be the increase in circulating E2 concentrations which begin to increase a few hours 
after transition and the decreasing P4 beginning at transition [52]. 
In mares the PGF2α pulse that initiates luteolysis (transitional pulse) is relatively small 
(approximately 50 pg/ml). Approximately eight hours before the transitional pulse, the CL is 
exposed in the majority of the mares (67%) to two or three preluteolytic PGFM pulses similar 
in magnitude to the transitional pulse at a mean of peak to peak interval of 8 hours, but 
luteolysis is not initiated at this time [52]. The absence of PGFM pulses during preluteolysis in 
33% of the mares and the small pulses in the other 67% indicate that the PGFM pulses during 
preluteolysis are not physiologically essential to subsequent luteolysis in mares [52]. In 
addition, rhythmicity of PGFM pulses was not detected during preluteolysis, but was detected 
in seven of nine mares during luteolysis and postluteolysis [52]. Other temporally related 
hormones or factors seem to be involved in the initiation of luteolysis in mares by increasing 
the response of the CL to the small PGFM pulse at the hour of transition in mares [50,52]. 
Cortisol and E2 were associated temporally with a PGFM pulse during luteolysis but not with 
a pulse during preluteolysis or with the transitional pulse [57]. Estradiol does not begin to 
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increase until 5 hours after the transitional pulse [52]. Oxytocin concentrations don’t increase 
during the last PGFM preluteolytic pulse, but they increase and decrease simultaneously with 
the ascending and descending portion of the PGFM transitional pulse and with the first PGFM 
luteolytic pulse. The oxytocin increase seems to account at least partly for the decrease in P4 
concentrations at the moment of transition from preluteolysis to luteolysis [50,57]. Oxytocin is 
synthesized in the hypothalamus and stored in the posterior pituitary. It is secreted in a pulsatile 
way, but its regulation during luteolysis is still unknown [58,59]. In mares the ovary is not a 
source of oxytocin contrarily to what is seen in domestic ruminants, where the CL synthesizes 
and secretes oxytocin during the estrous cycle [60,61]. The studies made to clarify oxytocin’s 
role during the estrous cycle showed that it appears to have a role in mares’ luteolysis as the 
intermediary that stimulates PGF secretion from the uterus [58,59]. However, it is not clear if 
oxytocin has a crucial role in the beginning of luteolysis. 
In mares, P4 concentrations during luteolysis decrease linearly during the hours of a 
PGFM pulse and between the ending nadir of a pulse and the beginning nadir of the next pulse 
[52,62,63]. Substantial pulses of LH are detected during preluteolysis and luteolysis. During 
luteolysis, LH concentration approximately doubles relatively to preluteolysis. However, 
concentrations of P4 don’t increase within the 3 to 5 hours of an LH pulse, and a P4 fluctuation 
does not occur in synchrony with the LH pulse [52]. 
Concentrations of P4 ≤ 0.9 ng/mL are used to represent postluteolysis. Progesterone 
continues to slowly decline after the defined end of luteolysis. The decline in P4 from 0.9 to 
0.1 ng/mL requires 22 to 32 hours [52]. It is unknown if the prominent PGFM pulses after the 
defined end of luteolysis are needed for the slow continuation of the decrease in P4 output by 
the corpus luteum or are used for another purpose [52]. 
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1.2.3. Abnormalities of the estrous cycle 
 
a) Hemorrhagic anovulatory follicles 
 
A hematoma that forms in the antrum of a follicle instead of ovulation has been termed 
a hemorrhagic anovulatory follicle (HAF). Most of HAFs have a peripheral wall of luteal 
tissue, as indicated by echotexture [48]. A distinguishing feature between a corpus 
hemorrhagicum and an HAF is the clotting of blood immediately during extravasation into the 
evacuated antrum or developing corpus luteum versus delayed clotting when blood enters 
follicular fluid [64]. Also, anovulation is a requisite component of the HAF syndrome. In this 
regard, no pregnancies occurred in 71 inseminated mares that developed an HAF [65]. The 
oocyte is not discharged into the oviduct before or during HAF formation, but whether oocytes 
are trapped or detrimentally affected in septated evacuations is not known. The incidence of 
hemorrhagic anovulatory follicles is approximately 5% and 20% of estrous cycles during the 
early and late ovulatory season, respectively and are especially common (36%) in mares 20 or 
more years old [64]. In addition, 44% of the mares that formed an HAF repeated the formation 
during a subsequent estrous cycle [64]. An HAF can occur without a simultaneous  ovulation 
or a second HAF during the late follicular phase, in conjunction with ovulation of another 
follicle, or during the luteal phase [64]. 
The morphology of ovulatory-sized follicles that formed HAFs during the late follicular 
phase has been compared with those of a solitary follicle that ovulated [66]. The diameter of a 
preovulatory follicle or future HAF one day before ovulation or formation of HAF, 
respectively, was similar between the two groups. The HAF formation involves entry of blood 
into a follicle that does not have altered structure. In addition, the follicle cells are viable, as 
indicated by luteinization of the wall of the HAF (luteinization is based on echotexture and 
approximately normal P4 production). However, the percentage of follicle wall with color 
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Doppler signals one day before ovulation or HAF formation was greater for the HAF group. 
The difference between the two groups in percentage of wall with color signals was attributable 
to vascularization of the follicle wall in the area of expected ovulation (apical area) in mares 
that formed an HAF but not in mares that ovulated. A difference in vascularity at the apex is 
compatible with null or minimal hemorrhage during ovulation and massive hemorrhage during 
HAF formation [64]. Concentrations of FSH, LH, and P4 were not different before ovulation 
between mares that developed HAF and mares that ovulated [66]. In both groups, the 
preovulatory E2 surge reached a peak two days before ovulation or anovulation or 3 days before 
the peak of the LH surge, as expected for ovulating mares [39]. Endometrial echotexture on the 
day of HAF formation is not different for mares that do not develop HAF. However, E2 was 
higher for mares that developed an HAF 3 days before HAF formation [66]. The role of 
elevated E2 in the formation of the HAF is not known. 
Increased thickness of the wall of the expanding HAF presumably represents luteal 
tissue and is associated with P4 production during HAF development. The luteinized wall is 
well vascularized, and the vascularization remains extensive as the structure regresses. 
Circulating P4 concentrations increase from 1 day before to the day of formation of the HAF, 
similarly to what is observed for an ovulation. In addition, the length of the luteal phase and 
interovulatory intervals are similar between mares that develop an HAF and mares that ovulate 
[64]. 
 
b) Idiopathic persistence of the corpus luteum 
 
As referred previously, luteolysis in mares begins in average 14 days after ovulation 
(range Day 14 to 16). A CL that fails to regress during the expected time of luteolysis in a non-
pregnant mare is considered to be pathologically persistent [67]. This condition can affect 25% 
of estrous cycles [2]and can be related to ovulations late in diestrous, embryonic loss after the 
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time of maternal recognition of pregnancy and chronic uterine infections. However, this 
condition can be observed without any of these conditionants [67], and this is named as 
idiopathic persistent CL. A wide spectrum of terminology has been used throughout the years 
to name this syndrome. Terms as persistent corpus luteum, prolonged diestrus, prolonged luteal 
activity or pseudopregnancy were used for similar conditions that if analyzed carefully may 
differ from each other [68]. Animals presenting persistent CL have P4 concentrations >1 ng/ml 
for about 63 days (range: 35 to 95 days) [2,68-70]. 
The idiopathic persistent CL has been suggested to be associated with low 
concentrations of PGF2α secreted from the uterus in the days that luteolysis is expected to 
occur, but the mechanism behind this condition is still unknown [2,68,71]. Most of the studies 
done in this area were made before the availability of ultrasound technology, so it was difficult 
to know if the cause of the prolonged diestrus was a prolonged primary CL (CL formed from 
a follicle that ovulated at the last estrus), a CL derived from an ovulation late in diestrus (CL 
is immature and subsequently non-responsive to PGF2α secreted at the normal time of 
luteolysis) or from an hemorrhagic anovulatory follicle with luteinized tissue [68]. Further 
studies with maintenance of the identity of the primary CL will be needed to characterize the 
mechanism that leads to idiopathic persistent CL. 
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Abstract 
 
A procedure for oxytocin (OT) administration on Day 13 postovulation was developed 
in mares for stimulation of a pulse of PGFM (a PGF2α metabolite) that mimics a natural PGFM 
pulse during luteolysis. Bolus treatment with each of five OT doses (1 to 10 IU/mare, n = 3) 
stimulated a burst of PGFM that was maximum in 4 min and was unlike a natural pulse. A 2-h 
OT infusion of 1.25, 2.5 or 5 IU/100 kg (n = 4) induced a PGFM pulse similar to reported 
pulses; lower doses did not. The peak of an induced pulse (~260 to 380 pg/mL) seemed similar 
to reported natural peaks (~200 to 300 pg/mL), using the same assay system. The interval from 
nadir to nadir was 6.6 ± 0.2 h. Percentage decrease in progesterone (P4) within 8 h was greater 
(P < 0.05) for doses of 1.25, 2.5 or 5 IU/100 kg (43 to 50%) than for a vehicle group (11%). 
Treatment with flunixin meglumine (1.0 mg/kg), a cyclooxygenase inhibitor, decreased (P < 
0.008) PGFM concentration but treatment 2 h before the beginning of OT infusion (2.5 IU/100 
kg) did not prevent the OT-induced PGFM pulses and the decrease in P4. In conclusion, a 
PGFM pulse was simulated by infusion of OT during 2 h but not by a single OT bolus, and an 
OT-simulated PGFM pulse stimulated a decrease in P4 that was not prevented by a 
cyclooxygenase inhibitor. These are the first firm demonstrations that OT in mares as in other 
species has a role in luteolysis. 
 
Keywords: Luteolysis; Mares; Oxytocin; PGFM; Progesterone. 
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2.1. Introduction 
 
The regression of the corpus luteum (CL) or luteolysis is a pivotal reproductive event 
during the estrous cycle in farm species, including mares. Luteolysis represents a decrease in 
progesterone (P4) from the response of the CL to the secretion of prostaglandin F2α (PGF2α) 
by the endometrium (review [1]). In the mare, luteolysis begins on average on Day 14 (Day 0 
= ovulation) and lasts 23 h based on hourly blood sampling [2]. The end of luteolysis is defined 
as a P4 decrease to < 1 ng/mL [3]. The main plasma PGF2α metabolite is 15-keto-13,14-
dihydro-prostaglandin F2α (PGFM) [4]. The metabolite has a longer half-life and is often used 
to represent circulating concentrations of PGF2α [5]. In many species, including mares, 
complete luteolysis requires secretion of multiple pulses of PGF2α by the nongravid uterus [6]. 
The interval between the peaks of sequential PGFM pulses in mares is 9 h and the interval from 
nadir to nadir at the PGFM base is 5 h [6]. Inhibition of PGF2α secretion at the expected time 
of luteolysis with a cyclooxygenase inhibitor (flunixin meglumine) induces a delay in the 
beginning of luteolysis [7].  
Based on hourly blood sampling, the transition into the luteolytic period in mares is 
manifested within 1 h [8]. Pulses of PGFM are relatively small before luteolysis (e.g., peak 30 
ng/mL) compared to during luteolysis (e.g., 190 ng/mL) [8]. Each PGFM pulse that occurs 
during luteolysis is temporally associated with a pulse of oxytocin (OT) [9]. The small 
transitional pulse at the hour of the initiation of luteolysis is also associated with a pulse of OT, 
whereas previous small PGFM pulses are not [10]. Oxytocin therefore may play a role in the 
effectiveness of a PGF2α pulse during luteolysis as well as the effectiveness of the small 
transitional pulse at the initiation of luteolysis in mares (review [2]).  
Oxytocin is synthesized in the hypothalamus, stored in the posterior pituitary, and 
secreted in pulses [11,12]. The CL also synthesizes and secretes OT during the estrous cycle in 
domestic ruminants [13,14], but the CL apparently does not secrete OT in mares [15]. 
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Circulating concentration of OT in mares is greater at the expected time of luteolysis (Day 15) 
than before luteolysis (Days 0, 3, or 7) [12]. The role of OT during spontaneous luteolysis has 
not been clarified in mares, but in other farm species OT is an intermediary in the stimulation 
of PGF2α secretion from the uterus (review, [16]). In previous studies on the effect of 
exogenous OT on PGFM in mares, the doses were apparently based on clinical 
recommendations (e.g., 20 IU to evacuate the uterus [17]). Treatment of nonpregnant mares 
with OT doses of 10 to 25 IU [18-21] or the OT response to uterine biopsy [22,23] stimulates 
an increase in PGFM. The OT treatments are especially effective near the expected day of 
luteolysis when the number of uterine OT receptors is maximum (Days 14 to 17) [22–24]. 
Despite the induced increase in PGFM, a negative effect of OT treatment on circulating P4 
concentration has not been documented in mares. 
Treatment with OT early in the estrous cycle in cattle is luteolytic [25], but in mares 
treatment on Days 1 through 7 with a high dose (200 IU [26]) or on Days 4 to 8 (150 IU [27]) 
did not induce luteolysis or shorten the interovulatory interval (IOI). In this regard, the number 
of OT receptors in the uterus is minimal on Days 4 to 8 in mares [27]. Despite the stimulation 
of PGFM by OT doses of 10 to 25 IU/mare [18,20], chronic administration of OT in high doses 
(e.g., 60 IU/day on Days 7 to 14) prolongs the luteal phase at least until Day 30 [28–31]. 
Furthermore, 60 IU of OT on Days 8 to 14 prolongs the luteal phase (P4 > 1.0 ng/mL through 
Day 30), reduces endometrial cyclooxygenase-2 expression, and lowers plasma concentrations 
of PGFM [31]. 
The dose and method of OT administration that could be considered physiologic in 
mares are unknown. That is, the effect of OT treatment on the CL has been examined only on 
a pharmacologic basis. The objectives for the current studies in mares were (1) to determine a 
dose and method of administration of OT that will stimulate a PGFM pulse similar to a 
spontaneous pulse and (2) to study the role of OT in luteolysis. The hypotheses were (1) 
simulation of a PGFM pulse can be done by infusion of a specific dose of OT during 2 h but 
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not by a single OT bolus dose, (2) OT induction of a simulated PGFM pulse stimulates a 
decrease in P4, and (3) OT exerts a luteolytic effect only through stimulation of PGF2α 
secretion. 
 
2.2. Materials and methods 
 
2.2.1. Mares and treatments 
 
  Mixed breeds (light, riding-type horses and apparent pony-horse crosses) of 21 
nonlactating mares aged 4 to 18 y and weighing 300 to 600 kg were used in the northern 
temperate zone. Abnormalities of the reproductive tract were not detected by transrectal 
ultrasonic scanning [32]. The mares had not been bred for at least 3 y. The mares were housed 
under natural light in an open shelter and outdoor paddock and were maintained by free access 
to primarily grass hay, trace-mineralized salt, and water. All mares remained healthy and in 
good body condition throughout the studies. Animals were handled according to the United 
States Department of Agriculture Guide for Care and Use of Agricultural Animals in 
Agricultural Research and Teaching. Mares were examined daily throughout each of four 
experiments by transrectal ultrasonic imaging as described [32]. A duplex B-mode (gray scale) 
and color-Doppler instrument equipped with a linear-array 7.5-MHz transducer was used. The 
day of ovulation was designated Day 0.  
Mares were assigned by randomization to experimental groups, including a vehicle or 
control group (0 dose). Each designated treatment in each experiment was given into a jugular 
vein. Oxytocin (Oxytocin injection®, Bimeda, Inc., Le Sueur, MN, USA) was used in each 
experiment. Flunixin meglumine (FM; FluMeglumine, Phoenix, St Joseph, MO, USA) was 
also used in experiments 3 and 4. The FM acts on cyclooxygenase enzymes in the endometrium 
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[33] and thereby blocks PGF2α synthesis [34]. A single systemic treatment with FM inhibits 
PGF2α secretion in the mare, but the effect wanes by 8 h [7].  
 
2.2.2. Experiment 1. Effect of bolus treatment with OT on PGFM 
 
This experiment was done to determine if a single injection of OT would induce a pulse 
of PGFM that would be similar to an endogenous pulse. On Day 13, mares in a vehicle group 
were given 2 mL of saline, and mares in five OT-treated groups were given a single bolus 
treatment of OT as follows: OT-1.0 (1.0 IU of OT/mare), OT-2.5, OT-5, OT-7.5 and OT-10.0 
(n = 3/group). The doses of OT were diluted in saline to a final volume of 2 mL for each dose. 
The minute of the treatment was designated Minute 0. Blood samples were collected into 
heparinized tubes by venipuncture of the jugular vein. The mares were docile and did not object 
to venipuncture with a 20-gauge needle, as indicated by collection without head restraint. 
Samples were collected at Minutes 0, 1, 2, 3, 4, 5, 10, 15, 30, 45, and 60 and hourly thereafter 
until Hour 4. The Minute 0 sample was collected immediately before treatment. Plasma 
samples were assayed for PGFM.  
 
2.2.3. Experiment 2. Effect of 2-h infusion of OT on PGFM pulses 
 
This experiment was done to determine a dose of OT that would simulate an 
endogenous pulse of PGFM when infused for 2 h. An infusion period of 2 h was selected 
because a 2-h infusion of PGF2α approximately simulates a PGFM pulse in mares [35]. On 
Day 12, an indwelling catheter was inserted into a jugular vein as described [8]. On Day 13, 
vehicle (n = 8) or a specified dose of OT (n = 4/group) was infused into the vein during 2 h. 
The doses for the OT-treated groups were OT-0.05 (0.05 IU of OT/100kg), OT-0.5, OT-1.25, 
OT-2.5, and OT-5.  
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The beginning of the infusion was designated Hour 0. Infusion of OT was done at a 
constant rate using a variable-flow peristaltic minipump (Number 18-876-4; Fisher Scientific, 
Pittsburgh, PA, USA). The pump was calibrated to deliver the specified dose of OT in 8 mL of 
saline vehicle during 2 h. During the infusion, the mare was confined in a chute but the head 
was not restrained. Ten hourly blood samples were collected from Hours –1 through 8, and a 
last sample was collected at Hour 48. Determination was made of the lowest dose of OT that 
simulates a PGFM pulse that is similar to a reported [6,8] spontaneous PGFM pulse during 
luteolysis. Blood samples were assayed for PGFM and P4.  
Pulses of PGFM were identified in each set of hourly blood samples. To distinguish 
between fluctuations and pulses, the intra-assay coefficient of variation (CV) was used as 
described [36]. Each PGFM fluctuation with an increase and decrease encompassing at least 
four hours, including nadirs, was evaluated. A fluctuation was defined as a pulse when the CV 
was at least three times greater than the mean intra-assay CV. The first defined pulse with a 
peak after Hour 0 was used in the analyses. The peak of an identified PGFM pulse was 
designated 0 hour. 
 
2.2.4. Experiment 3. Effect of FM bolus treatment and OT infusion on P4. 
 
This experiment was done to determine if FM treatment before and after OT infusion 
would have an effect on P4 concentration. Four groups (n = 3 or 4/group) were used: control 
(no vehicle), FM (1.0 mg/kg), OT (2.5 IU of OT/100kg), and FM/OT (1.0 mg/kg FM, and 2.5 
IU of OT/100kg). On Day 12, about 16 h before treatment on Day 13, an indwelling catheter 
was inserted into a jugular vein as for experiment 2. The FM was given on Days 13.0 and 13.3 
(8 hours after Day 13.0), and a 2-h infusion of the dose of OT was begun 2 h after the first FM 
treatment. Blood samples were collected on Days 13.0, 13.3, 14 and 15 and were assayed for 
P4. 
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2.2.5. Experiment 4. Effect of FM bolus treatment and OT infusion on PGFM and P4. 
 
This experiment was done as a follow-up to experiment 3 to determine if blood 
sampling at hourly intervals would better determine the effect of OT and FM on P4 and to 
detect and characterize PGFM pulses. The beginning of the 2-h OT infusion was designated 
Hour 0. The groups (n = 5 mares/group) and protocol were the same as for experiment 3, except 
that 11 hourly blood samples were collected from Hours –2 to 8 and at Hour 24. The FM was 
administered at Hours –2 and 4. Plasma samples were assayed for PGFM, and PGFM pulses 
were identified as described for experiment 2. Samples were also assayed for P4 to determine 
if OT alone had at least a partial luteolytic effect.  
 
2.2.6. Hormone assays 
 
Blood samples were immediately placed in ice water for 10 min after collection 
followed by centrifugation (2,000 X g for 10 min). The plasma was decanted and stored (–20º 
C) until assayed. Plasma samples were assayed for P4 by a solid-phase RIA kit containing 
antibody-coated tubes and 125I-labeled P4 (Coat-A-Count Progesterone, Diagnostic Products 
Corporation, Los Angeles, CA, USA). The procedure has been validated and described for 
mare plasma in our laboratory [37]. Plasma concentrations of PGFM were determined by an 
ELISA that was developed and validated in our laboratory for use in mare plasma [38]. For 
PGFM in experiment 1, the intra- and interassay CV and sensitivity, respectively, were 5.2%, 
17.1%, and 4.6 pg/mL. For PGFM in experiment 2, the intra- and interassay CV and sensitivity, 
respectively, were 14.5%, 12.1%, and 5.8 pg/mL, and for P4 the intra-assay and sensitivity, 
respectively, were 5.5% and 0.03 ng/mL. For P4 in experiment 3, the intra- and interassay CV 
and sensitivity, respectively, were 7.9%, 4.3%, and 0.02 ng/mL. For PGFM in experiment 4, 
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the intra- and interassay CV and sensitivity, respectively, were 18.0%, 18.9%, and 6.6 pg/mL, 
and for P4 the intra-assay CV and sensitivity, respectively, were 7.2% and 0.03 ng/mL. 
 
2.2.7. Statistical analyses 
 
Data were examined for normality using the Shapiro-Wilk test. Data that were not 
normally distributed were resolved by transformation to natural logarithms or ranks. The rank 
transformation was used when logarithms did not resolve a lack of normality. A value defined 
as an extreme outlier by the interquartile range analysis was removed from the analyses and 
figures. Determination was made of the main effects of group and time (day, hour, or minute) 
and the interaction of group and time. The statistical analyses were done by using SAS PROC 
MIXED (Version 9.3; SAS Institute Inc., Cary, NC, USA) with REPEATED statement, owing 
to repeated measures in each mare. Autocorrelation was accounted for by modeling the first-
order autoregressive or spatial power between sequential measurements. When a factor or 
interaction was significant or approached significance, least significant difference from the 
SAS procedure was used for comparisons among patterns within a time and to compare times 
within a group. Student’s paired and unpaired t-tests were also used but on a preliminary basis. 
Either chi-square or Fisher’s exact test was used at the discretion of the computer program to 
determine differences in frequency among groups in the proportion of PGFM pulses and for 
the proportion of mares that ended luteolysis on a given day. A probability of P ≤ 0.05 indicated 
that a difference was significant, and a probability of P > 0.05 to ≤ 0.10 indicated that 
significance was approached. Differences that approached significance were included on a 
preliminary basis for potential consideration in further studies. Data are presented as the mean 
± SEM, unless otherwise indicated. 
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2.3. Results 
 
2.3.1. Experiment 1. Effect of bolus treatment with OT on PGFM 
 
One outlier in PGFM concentration in the OT-2.5 group at Minute 1 was omitted from 
the analyses and figure. Concentrations of PGFM after a bolus injection of vehicle and various 
doses of OT had an effect of minute and a group-by-minute interaction for Minutes 0 to 45 
(Fig. 2.1). The highest PGFM concentration was observed at Minute 4 after treatment in all 
OT-treated groups. The group-by-minute interaction was represented by greater concentration 
in each OT-treated group than in the vehicle group at Minutes 3 to 15 but not at Minutes 0, 1, 
2, 30, and 45. The peak at Minute 4 was not different among the OT-treated groups. 
Concentration at Minute 45 was not different from the pretreatment concentration for each OT-
treated group. Concentrations did not increase during the hourly samples (not shown). 
 
 
Figure 2.1. Mean ± SEM concentrations of PGF2α metabolite (PGFM) from Minutes 0 to 45 
(Minute 0 = bolus treatment) in a vehicle and oxytocin-treated (OT) groups (e.g., OT-1 = OT 
at 1.0 IU/mare). Probabilities for main effects of group (G) and minute (M) and the interaction 
of group by minute (GM) are shown. Concentration was greater in each OT-treated group than 
in the vehicle group at Minutes 3 to 15, but the differences among OT groups were not 
significant.  
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2.3.2. Experiment 2. Effect of 2-h infusion of OT on PGFM pulses 
 
Concentration of PGFM had a significant main effect of hour, an effect of group that 
approached significance, and a significant group-by-hour interaction (Fig. 2.2). The hour effect 
reflected maximal PGFM concentration at Hours 1 or 2. The approaching group effect reflected 
greater (P < 0.05) concentration in the three groups with the highest doses of OT. The group-
by-hour interaction was primarily from greater (P < 0.05) PGFM concentration at Hours 1 and 
2 in the groups OT-1.25, OT-2.5, and OT-5 than in the other groups. 
 
 
Figure 2.2. Mean ± SEM concentrations of PGF2α metabolite (PGFM) and progesterone (P4) 
at hourly intervals in a vehicle (n = 8) and oxytocin-treated (OT) groups (n = 4/group) at the 
indicated dose (e.g., OT-0.5 = OT at 0.5 IU/100 kg). The vehicle and OT were infused for 2 h 
as indicated above the hour scale. Probabilities for main effects of group (G) and hour (H) and 
an interaction (GH) are shown. Within each hour, any two means without a common letter 
(abc) are different (P < 0.05); a ring is used to encompass two means that are too close for 
placement of separate letters.  
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A PGFM pulse was detected by the CV method in 4 of 8 mares treated with vehicle, 
compared to 18 of 20 mares treated with OT (P < 0.04). Concentrations in the PGFM pulse 
from 2 h before to 2 h after the peak had significant main effects of group and day and an 
interaction (Fig. 2.3). The group effect was from greater (P < 0.05) concentration in each of the 
three highest OT doses (combined, 144.8 ± 21.8 pg/mL) than for each of the two lowest doses 
(combined, 34.2 ± 7.0 pg/mL); the vehicle group was intermediate (75.6 ± 12.2 pg/mL). The 
interaction was primarily from greater (P < 0.05) PGFM concentration at the peak (0 hour) for 
each of the three highest doses than for each of the other three groups (Table 2.1) and no 
difference at –2 and 2 h; significant differences among groups at –1 and 1 hours are shown 
(Fig. 2.3). Amplitude of the pulses from the beginning nadir to the peak was greater in each of 
the three highest dose groups than in each of the other three groups, but the nadir-to nadir 
interval was not different among groups (Table 2.1). The nadirs at the beginning and end of a 
pulse were not significantly different among groups (not shown). 
 
 
Figure 2.3. Mean ± SEM concentrations of PGF2α metabolite (PGFM) in identified pulses 
centered on the pulse peak in a vehicle and oxytocin-treated (OT) groups at the indicated dose 
(e.g, OT-5 = OT at 5 IU/100 kg). Probabilities for main effects of group (G) and hour (H) and 
an interaction (GH) are shown. Within each hour, any two means without a common letter 
(abc) are different (P < 0.05); a ring is used to encompass two means that are too close for 
placement of separate letters.  
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Table 2.1. Mean ± SEM for pulse characteristics of PGFM pulses during an 8 h period of 
hourly sampling in mares in vehicle and OT-treated groupsa.  
Groupa 
Pulse characteristics 
Peak 
(pg/mL) 
Amplitude 
(pg/mL) 
Mean for all 
hours (pg/mL)b 
Nadir-to-nadir 
interval (h) 
Vehicle  126.3 ± 31.9d 92.9 ± 18.3d   66.7 ± 16.0cd 5.3 ± 0.8 
OT-0.05    59.3 ± 8.2d 42.3 ± 4.3d   33.5 ± 7.5de 6.0 ± 0.0 
OT-0.5    72.5 ± 15.3d 66.3 ± 13.5d   21.9 ± 6.5e 5.5 ± 0.7 
OT-1.25  382.4 ± 182.2c 349.8 ± 173.4c 124.1 ± 58.6c 6.3 ± 0.3 
OT-2.5  367.0 ± 80.0c   336.9 ± 67.3c 101.5 ± 14.7c 6.8 ± 0.5 
OT-5  263.2 ± 31.6c   220.0 ± 41.5c 112.7 ± 6.9c 6.8 ± 0.5 
Probabilityf P < 0.0004 P < 0.0002 P < 0.0003 NS 
     
a Each dose of oxytocin (OT) was infused iv during 2 h (e.g., OT-0.05 = 0.05 IU/100 kg 
of OT) (n = 3 or 4/group). 
b Differs from the group effect of Figure 2.3 because the figure was limited to –2 to 2 h 
from the peak, and this table encompasses all hours from nadir to nadir. 
cde For each column, means of PGFM pulse characteristics with no common superscript 
letter are different (P < 0.05). 
f Probability for a difference among groups for each column. Each nadir was not 
significantly different among groups and is not included. 
 
For P4 concentration, the group effect approached significance and the hour effect and 
interaction were significant (Fig. 2.2). The approaching group effect averaged over hours 
reflected no difference among the OT-0.5, OT-1.25, and OT-2.5 groups, but less (P < 0.05) 
concentration in each of these OT groups (combined, 7.7 ± 0.2 ng/mL) than in the OT-0.05 
group (10.2 ± 0.3 ng/mL) and vehicle group (9.7 ± 0.3 ng/mL). Concentration of P4 in each of 
the OT-0.05 and OT-5 groups was not different from the vehicle group. The interaction of 
group and hour represented no differences among groups for each of Hours –1 to 2, less P4 in 
the OT-0.5 group than in the vehicle group at Hour 3, and less P4 in the OT-0.5 and OT-1.25 
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groups but not in the OT-2.5 and OT-0.5 groups than in the vehicle group at Hour 4. The 
indicated differences among groups at Hours 5 to 8 contributed to the interaction. Most notably, 
each of the vehicle and OT-0.05 groups had greater P4 concentration than each of the other 
four groups at Hours 7 and 8, including the OT-0.5 group. However, the OT-0.5 group had the 
lowest P4 concentration before OT was infused. Therefore, percentage decrease from Hours –
1 to 8 was also analyzed. The percentage P4 decrease was greater (P < 0.05) for the three 
highest doses (43 to 50% decrease) than for the vehicle (11% decrease) and the lowest dose 
(4% decrease), but the decrease (22%) for OT-0.5 dose was not different from any other group. 
The proportion of mares with P4 < 1 ng/mL at Hour 48 (Day 15) was as follows: vehicle, 3/8; 
OT-0.05, 1/4; OT-0.5, 2/4; OT-1.25, 3/4; OT-2.5, 4/4; and OT-5, 2/4. The proportion 
approached being significantly greater (P < 0.08) in the OT-2.5 group than in the vehicle group, 
but the other OT-treated groups were not different from the vehicle group. 
 
2.3.3. Experiment 3. Effect of FM bolus treatment and OT infusion on P4 
 
One mare from the control group and one mare from the FM/OT group were omitted 
from the analyses because luteolysis was underway on Day 13.0. The percentage change from 
Day 13.0 (first FM treatment) was used for P4 concentration because of apparent differences 
among groups on Day 13.0. Percentage change in P4 concentration on Day 13.3 (8 hours after 
first FM treatment) to Day 15 had a significant effect of day and a group-by-day interaction 
(Fig. 2.4). The group-by-day interaction was primarily from greater (P < 0.05) percentage P4 
decrease in the OT and FM/OT groups than in the control and FM groups on Day 13.3, greater 
(P < 0.04) change in the OT than in the FM group on Day 14, and similarity among groups on 
Day 15. Actual concentration of P4 decreased (P < 0.05) between Days 13.0 and 13.3 in the 
OT group (12.7 ± 1.6 to 7.5 ± 1.2 ng/mL) and FM/OT group (11.0 ± 2.3 to 7.0 ± 2.5 ng/mL) 
52 
 
but not in the control and FM groups. The day of end of luteolysis and the length of the 
interovulatory interval were not different among groups. 
 
 
Figure 2.4. Mean ± SEM percentage of change from Day 13 in concentration of progesterone 
(P4) in control, flunixin meglumine (FM), oxytocin (OT), and FM/OT groups. An FM 
treatment (1.0 mg/kg) was given on Days 13.0 and 13.3, and OT was infused (2.5 IU/100 kg) 
during 2 h beginning 2 h after the first FM treatment. Probabilities for main effect of day (D) 
and an interaction (GD) are shown. Within each day, any two means without a common letter 
(ab) are different (P < 0.05).  
 
2.3.4. Experiment 4. Effect of FM bolus treatment and OT infusion on PGFM and P4 
 
Concentration of PGFM had significant main effects of group and hour and a group-
by-hour interaction (Fig. 2.5). The group effect was represented by the following 
concentrations (pg/mL): control (26.8 ± 2.7a), FM (9.6 ± 0.6b), OT (81.1 ± 24.0c), and FM/OT 
(69.5 ± 23.2c); means with different superscripts are different (P < 0.05). The group-by-hour 
interaction was primarily from greater (P < 0.05) PGFM concentration at Hours 1 and 2 in the 
OT and FM/OT groups than in the other two groups and greater (P < 0.05) concentration at 
Hours 1, 3, 6, 7, and 8 in the controls than in the FM group; other differences are shown. A 
PGFM pulse was detected by the CV method in 1 of 5, 0 of 5, 4 of 5, and 5 of 5 mares in the 
control, FM, OT, and FM/OT groups, respectively (P < 0.004). Concentrations in the PGFM 
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pulses averaged over 2 h before to 2 h after the peak, at the peak, nadirs at the beginning and 
end of a pulse, and amplitude from nadir 1 to the peak were not different between the OT and 
FM/OT groups (not shown). 
 
 
Figure 2.5. Mean ± SEM concentrations of PGF2α metabolite (PGFM) and progesterone (P4) 
on Day 13 in control, flunixin meglumine (FM), oxytocin (OT), and FM/OT groups. The 
PGFM concentration is in two different scales. An FM treatment (1.0 mg/kg) was given at 
Hours –2 and 4 and OT was infused (2.5 IU/100 kg) during 2 h beginning at Hour 0. 
Probabilities for main effects of group (G) and hour (H) and an interaction (GH) are shown for 
PGFM and P4. Within each panel and hour, any two means without a common letter (abc) are 
different (P < 0.05).  
 
 
For P4 concentration, the hour effect and interaction were significant (Fig. 2.5). The 
interaction of group and hour represented no differences among groups for each of Hours –2 
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to 6, less P4 in the OT than in the control and FM groups at Hour 7, and less P4 in the OT and 
FM/OT groups than in the FM group at Hour 8. When analyzed separately, concentration of 
P4 decreased between Hour 0 and 8 in the OT (P < 0.007) and FM/OT (P < 0.04) groups but 
not in the control and FM groups. The first significant decrease (P < 0.001) in the control group 
occurred between Hours 8 and 24 (13.1 ± 2.9 to 9.0 ± 3.1 ng/mL), in the FM group (P < 0.0008) 
between Hours 8 and 24 (12.9 ± 1.8 to 9.7 ± 2.2 ng/mL), in the OT group (P < 0.003)  between 
Hours 3 and 4 (12.6 ± 2.1 to 10.5 ± 1.8 ng/mL), and in the FM/OT group (P < 0.05) between 
Hours 2 and 4 (15.5 ± 4.0 to 11.3 ± 2.0 ng/mL).  
 
2.4. Discussion 
 
In farm species, including horses, PGF2α is secreted from the endometrium at the 
appropriate time and stimulates luteolysis. In cattle and sheep, OT from the CL and 
hypothalamus binds to OT receptors in the endometrium, arachidonic acid is released from the 
cell membranes, and PGF2α is secreted [16]. A positive feedback loop between OT and PGF2α 
plays a critical role in luteal regression in these species [39]. However, in mares the role of OT 
in the regulation of uterine PGF2α secretion and P4 reduction during luteolysis has not been 
determined [39]. In the current studies, the effect of exogenous OT on PGFM and P4 
concentrations in mares was evaluated. First, a dose and method of OT administration was 
developed that would stimulate a PGFM pulse that was similar to a natural pulse during 
luteolysis. 
Hypothesis 1, that simulation of a PGFM pulse can be done by infusion of a specific 
dose of OT during 2 h but not by a single OT bolus dose, was supported. Constant infusion of 
a specific dose of OT during 2 h stimulated a pulse of PGFM that was similar to reported [6,8] 
spontaneous pulses during and immediately after luteolysis. The mean of the peak PGFM 
concentration of the OT-stimulated pulses (~260 to 380 pg/mL) was not different among the 
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three highest infused doses and was similar to the reported peaks of spontaneous pulses (~200 
to 300 pg/mL [8]). However, the base (nadir to nadir) seemed broader for the induced pulses 
(~6.6 h) than for reported pulses (~5.4 h [6]). 
In contrast to the response to OT infusion, bolus treatment in various doses induced a 
relatively short burst of PGFM that did not resemble a natural pulse. The burst reached 
maximum in 4 min compared to an ascending portion of a natural pulse of 2 to 3 h [6,8]. 
Although the maximal value at 4 min did not differ among the OT doses, the range of means 
(~300 to 600 pg/mL) encompassed the means for the OT-induced and reported spontaneous 
pulses. However, each of the ascending and descending portions of a spontaneous PGFM pulse 
require about 2.5 h, whereas the corresponding portions of the burst from a bolus treatment 
were 4 and 41 min, respectively. Clearly, a PGFM pulse can be approximately simulated by a 
2-h iv infusion of OT, but not by a bolus iv treatment. In this regard, the same assay system 
[8,38] was used for both the current and reported studies. In a previous study using an iv bolus 
of OT, the peak was reached in 10 min [21] or later than in the current study. However, the 
reported treatment was done on Days 0 and 2. The current study was done on a day (Day 13) 
that was close to the expected day of luteolysis (Days 14 or 15 [2]) and the beginning of an 
increase in number of uterine OT receptors [22–24]. 
Hypothesis 2, that OT induction of a simulated PGFM pulse stimulates a decrease in 
P4, was supported. Each of the three highest OT doses produced prominent PGFM pulses that 
were similar to natural pulses and induced a P4 decrease or percentage P4 decrease by Hour 8. 
This was shown by the average concentration/group and by the percentage P4 decrease between 
Hours –1 and 8. These results indicated that OT is an intermediary for secretion of PGF2α in 
mares, as previously shown for ruminants [16].The current results apparently represent the first 
firm demonstration of the luteolytic effect of exogenous OT in mares. In a previous study, 
chronic sc administration of OT beginning on Day 10 was associated with early luteolysis in 2 
of 5 mares compared to 0 of 4 controls; however, the number of mares was small and the 
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proportion of mares with early luteolysis was not significant [28]. The current successful 
demonstration is attributable to the infusion of physiologically compatible concentrations of 
exogenous OT, so that the resulting PGFM pulse was similar to a natural pulse during 
luteolysis. The induced decrease in P4 on Day 13 was not associated with a reduced length of 
the IOI, which is attributable to the reported necessity of multiple pulses of PGF2α for a 
continued decrease in P4 or complete luteolysis in mares [35]. 
On an observational and preliminary basis, the highest infused dose of OT (5 IU/100 
kg) may have been less effective in reducing P4 concentration than the lower doses of 1.25 and 
2.5 IU as indicated by the following: (1) apparent beginning of a mean P4 decrease (Hour 4) 
was later than for the doses of 1.25 and 2.5 IU (Hour 2) and (2) P4 concentration for the highest 
dose (5 IU) averaged over hours was not different from the vehicle and 0.05 IU dose and 
approached being greater than for the doses of 1.25 and 2.5 IU. Less effectiveness of a high 
dose of OT than a lower dose in stimulating a luteolytic PGFM pulse may be related to the 
induction of a persistent CL with chronic [28] or daily administration of OT in high doses (e.g., 
60 IU/mare [29–31]). In comparison, the three highest doses in the current project were 
equivalent to an average of 5, 10, and 20 IU/mare. The daily injection of pharmacologically 
high doses OT prevents luteolysis in association with suppression of PGF2α by a decrease in 
endometrial expression of cyclooxygenase-2 and not by a decrease in OT receptor expression 
[31] or differences in OT binding capacity of the endometrium [30]. 
Hypothesis 3, that OT exerts a luteolytic effect only through stimulation of PGF2α 
secretion, was not successfully tested. Support required that OT would not have a partial 
luteolytic effect after the prevention of the OT stimulation of PGF2α secretion by inhibiting 
cyclooxygenase enzymes with FM. This expectation was based on an in vitro report that a 
cyclooxygenase inhibitor (indomethacin) impeded the secretion of PGF2α in OT-stimulated 
equine endometrial explants [40]. In experiment 3, P4 decreased in both OT and FM/OT groups 
6 h after the beginning of OT infusion. However, blood samples were not available until 8 h 
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after FM treatment. Therefore, experiment 4 was done to obtain hourly samples to determine 
whether at least a partial P4 decrease would occur in the FM/OT group, despite inhibition of 
PGFM pulses. The effectiveness of FM in lowering PGFM concentrations on Day 13 (before 
the beginning of luteolysis) was verified within the experiment. The PGFM was lower in the 
FM group than in the controls, even though PGFM concentrations and pulses were minimal in 
controls on Day 13. However, FM did not block the PGFM pulse and P4 reduction of the 2-h 
infusion of 2.5 IU of OT. That is, the prominence of the OT-induced PGFM pulses and the P4 
decrease were similar between the OT and FM/OT groups. The P4 concentration began to 
decrease sooner and was lower in the OT and FM/OT groups at Hours 7 or 8 than in the control 
and FM groups. The FM did not suppress the negative effect of PGF2α (based on PGFM) on 
P4 concentration and therefore the hypothesis was not tested.  
The reason for the inability of FM to prevent OT stimulated PGF2α secretion was not 
determined. The inhibition of PGF2α secretion by FM is dose dependent [41]. The dose of FM 
was the same in the present and previous studies [7] and effectively inhibited PGF2α secretion 
in mares. In cattle and sheep, OT releases arachidonic acid (PGF2α precursor) from the 
phospholipid bilayer of endometrial cell membranes [16]. In addition, in vitro studies with 
endometrial epithelial cells have shown that OT has a dose-dependent positive effect on PGF2α 
production and gene expression for cyclooxygenase 1 and 2 [42,43]. The cyclooxygenase 
enzymes are rate-limiting in prostaglandin synthesis [44]. Therefore, it is speculated that OT 
may have increased the availability of cyclooxygenase, thereby overcoming the potential 
inhibitory effect of FM on cyclooxygenase. Further studies will be needed. 
 
2.5. Conclusions 
 
An increase in PGFM concentration occurred after an iv bolus treatment with OT on 
Day 13. Concentration of PGFM reached a peak within 4 min after treatment and returned to 
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pretreatment concentration in 45 min; the PGFM burst did not resemble a natural PGFM pulse. 
Infusion of OT (1.25, 2.5, or 5 IU/100 kg) during 2 h on Day 13 stimulated a PGFM pulse 
similar to the peak of a spontaneous PGFM pulse during luteolysis. Lower doses were not 
effective. The induced PGFM pulses stimulated a decrease in P4 concentration within 8 h after 
the beginning of OT infusion. Treatment with a cyclooxygenase inhibitor did not prevent the 
OT-induced PGFM pulses and the decrease in P4. Results demonstrated for the first time in 
mares that a physiologic dose and method of OT administration induces a PGFM pulse and a 
decrease in P4. 
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Abstract 
 
The effects of inhibition of PGF2α synthesis on luteolysis in mares and on the incidence 
of prolonged luteal activity were studied in controls and in a group treated with flunixin 
meglumine (FM), a PGF2α inhibitor (n = 6/group). The FM was given every 8 hours (1.0 
mg/kg) on each of Days 14.0 to 16.7. Concentration (pg/mL) of PGFM, a metabolite of PGF2α, 
averaged over 8 hours of hourly blood sampling at the beginning of each day was lower in the 
FM group than in the controls on Day 14 after ovulation (6.7 ± 1.3 vs 13.8 ± 2.9, P < 0.05), 
Day 15 (15.0 ± 3.9 vs 35.2 ± 10.4, P < 0.10), and Day 16 (21.9 ± 5.7 vs 54.7 ± 11.4, P < 0.03). 
Concentration (ng/mL) of progesterone (P4) was greater in the FM group than in the controls 
on Day 14 (10.1 ± 0.9 vs 7.7 ± 0.9, P < 0.08), Day 15 (9.2 ± 1.0 vs 4.3 ± 1.0, P < 0.008), and 
Day 16 (5.6 ± 1.6 vs 1.2 ± 0.4, P < 0.02). The interval from ovulation to the beginning of a 
decrease in P4 and to the end of luteolysis (P4 < 1 ng/mL) were each delayed (P < 0.03) by 
approximately 1 day in the FM group. Intervals involving the luteal phase were long (statistical 
outliers, P < 0.05) in two mares in the FM group, indicating prolonged luteal activity. Results 
supported the hypotheses that: (1) inhibition of PGF2α synthesis interferes with luteolysis in 
mares and (2) inhibition of PGF2α at the expected time of luteolysis may lead to prolonged 
luteal activity. 
 
Keywords: Mares; Luteolysis; PGFM pulses; Progesterone; Prolonged luteal activity
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3.1. Introduction 
 
 The decrease in progesterone (P4) or regression of the corpus luteum (CL) at the end 
of diestrus is a pivotal event during the estrous cycle in farm species including mares (reviewed 
in [1–4]). A 40-year chronology of research findings on the nature of luteolysis in mares has 
been reported [5]. Luteal terminologies before, during, and after the end of luteolysis are 
preluteolysis, luteolysis, and postluteolysis, respectively, and in mares, luteolysis occurs on 
Days 14 to 16 (Day 0 = ovulation) [6]. The transition between preluteolysis and luteolysis is 
manifested within 1 hour [7], based on P4 concentrations in blood samples collected hourly. 
The end of luteolysis and beginning of postluteolysis is commonly defined as a P4 decrease to 
< 1 ng/mL [6].  
 Luteolysis is a response to the secretion of PGF2α from the endometrium in the absence 
of an embryo [1,2]. In mares, as in other farm species, circulating concentrations of a PGF2α 
metabolite (PGFM) is often used to represent changes in PGF2α concentrations [8], owing to 
the short half-life of PGF2α [9]. Classical approaches to demonstrating that PGF2α is the 
luteolysin in farm species are: (1) administering PGF2α, (2) assaying circulating PGF2α 
concentrations, and (3) blocking PGF2α secretion. In mares: (1) luteolysis occurs after 
administration of PGF2α [10]; (2) at the expected time of luteolysis, an increase in PGF occurs 
in the uterine vein [11] and an increase in PGFM occurs in the systemic circulation [6,12,13]; 
and (3) removal of the site of PGF2α secretion (uterus) results in maintenance of the CL 
[14,15]. Administration of an inhibitor of PGF2α biosynthesis (flunixin meglumine, FM) has 
been done in ruminants [16], but systemic administration has not been used as an experimental 
approach for the study of luteolysis in mares. However, FM in mares prevents PGF2α secretion 
into the uterine lumen [17]. Systemic treatment with FM has been used to inhibit prostaglandin 
synthesis in mares during the follicular phase to induce hemorrhagic anovulatory follicles [18] 
and after insemination to alter uterine contractions [19]. The FM acts on the cyclooxygenase 
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enzyme in the endometrium [20] and thereby blocks PGF synthesis [21]. Phenylbutazone also 
inhibits the synthesis of PGF2α and has been used in attempts to alter CL function but without 
success [22].  
 Complete luteal regression in mares involves secretion of PGF2α in more than one 
pulse during the length of the luteolytic period, based on the P4 response to simulated PGFM 
pulses [23]. Therefore, PGFM pulses are an important consideration in the study of the 
luteolytic mechanism. Pulses of PGFM occur about every 9 hours during luteolysis and 
encompass 4 or 5 hours from beginning to ending nadirs [24]. During preluteolysis, PGFM 
concentrations remain below assay sensitivity or the identified pulses are small (e.g., 30 pg/mL 
peak) [6]. Pulse prominence increases considerably during luteolysis and postluteolysis (e.g., 
300 pg/mL). The peak of a small (e.g., 45 pg/mL) pulse occurs at or within 1 hour of the 
transitional hour between preluteolysis and luteolysis and may be similar in prominence to the 
previous pulse during preluteolysis [6]. Oxytocin increases in synchrony with the small PGFM 
pulse at the hour of transition and during prominent pulses of luteolysis but does not increase 
during the small pulses before the transitional pulse [25]. Concentrations of P4 decrease 
linearly within the hours of a PGFM pulse [13,26] and between the PGFM nadirs of adjacent 
pulses [24]. Luteal blood flow begins to decrease during the descending portion of a PGFM 
pulse [26].  
 Prolonged luteal activity or luteal persistence occurs in mares (reviewed in [1,2,27]). 
Persistent CL can result from impairment of uterine PGF2α secretion by severe uterine 
pathology [28]; this form of luteal persistence has been termed uteropathic [29]. Spontaneous 
[27,30] or idiopathic [29] persistent CL in mares that do not have known uterine pathology has 
also been reported, and the mean length of the luteal phase is approximately 2 months [30]. 
The incidence has been reported as 25% of estrous cycles [30] and as 8 to 10% but with a 
higher incidence (20 to 35%) near the end of the ovulatory season [31]. Although the 
pathogenesis of idiopathic luteal persistence is unknown, an impairment in the secretion of 
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PGF2α has been suspected [27,29,30]. Prolonged P4 production also occurs when a secondary 
CL forms from ovulation during diestrus, and the CL is too immature to respond to PGF2α 
secretion [29,30].  
 Inhibition of PGF2α biosynthesis has not been used in mares to study the role of PGF2α 
in luteolysis, and therefore FM was used in the current experiment during the expected time of 
luteolysis (Days 14 to 16). Hypotheses were: (1) inhibition of PGF2α synthesis interferes with 
luteolysis in mares and (2) inhibition of PGF2α at the expected time of luteolysis may lead to 
prolonged luteal activity.  The effect of FM on circulating P4 was based on concentrations 
when assessed daily or every 8 hours and by number and prominence of PGFM pulses in hourly 
samples. 
 
3.2. Materials and methods 
 
3.2.1. Mares 
 
  Mares were mixed breeds of nonlactating large ponies and apparent pony-horse 
crosses, aged 4 to 18 years and weighed 400 to 600 kg. The mares had not been bred for at least 
3 years. Abnormalities of the reproductive tract were not detected by ultrasonographic 
examinations [32]. The experiment was done in the summer (June). The mares were housed 
under natural light in an open shelter and outdoor paddock and were maintained by free access 
to primarily grass hay, trace-mineralized salt, and water. All mares remained healthy and in 
good body condition throughout the study. Mares were handled according to the United States 
Department of Agriculture Guide for Care and Use of Agricultural Animals in Agricultural 
Research and Teaching. 
 
69 
 
 
3.2.2. Protocol 
 
Mares were assigned randomly to a control group and an FM-treated group (n=8 
mares/group). Mares in the FM-treated group were given an iv treatment of FM (1.0 mg/kg) 
every 8 hours, whereas the mares in the control group were not treated. The dose of FM 
approximated the dose of 1.1 mg/kg that was recommended by the manufacturer and was 
experimentally used to block the role of PGF2α in uterine contractions [19]. Treatments were 
given on each of Days 14, 15, and 16 at 7 AM, 3 PM, and 11 PM (8-hour intervals). Days 14 
to 16 are the expected days of functional regression of the CL [6].  
Mares were examined daily from Day 11 until ovulation by gray-scale and color-
Doppler ultrasonography for determining luteal area (cm2) at the maximal cross-sectional 
plane, diameter of the two largest follicles in each ovary, endometrial score from 1 to 4 
(minimal to maximal) as an estimate of the extent of endometrial edema [32], and percentage 
of CL with color-Doppler signals for blood flow of the CL [33]. The percentage of the CL with 
color-Doppler signals of blood flow was estimated from a scan of the entire CL. A duplex B-
mode (gray scale) and color-Doppler ultrasound instrument (Aloka SSD 3500; Aloka 
American, Wallingford, CT) equipped with a linear-array 7.5 MHz transducer was used. Blood 
samples were collected into heparinized vacutainer tubes from a jugular vein. Samples were 
taken every day from Day 11 to ovulation and every 8 hours from Day 13 at 7 AM, 3 PM, and 
11 PM (Days 13.0, 13.3, and 13.7, respectively) until Day 17.0 (Fig. 3.1). In addition to 8-hour 
samples, blood samples were taken each hour for 8 hours on each of Days 14, 15, and 16 
beginning at 7 AM. The first sample in each 8-hour set was designated Hour 0 and was taken 
just before FM treatment. 
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Figure 3.1. Diagram of experimental protocol. Flunixin meglumine (FM,1.0 mg/kg) was given 
every 8 hours for a total of 9 treatments from Day 14 at 7:00 AM until Day 16 at 11:00 PM. 
Daily ultrasound examinations and blood sampling were done from Day 11 postovulation until 
ovulation. Blood samples were collected every 8 hours from Day 13 at 7:00 AM until Day 17 
at 7:00 AM. Three sets of hourly samples for 8 hours were collected on Days 14, 15 and 16 
from 7:00 AM until 3:00 PM. Ov, ovulation. 
 
Prolonged luteal activity was indicated if a statistical outlier occurred in the interval 
from ovulation to the beginning of luteolysis or from ovulation to the end of luteolysis (P4 < 1 
ng/mL). The day of the beginning of luteolysis was assigned to the 8-hour interval when P4 
began to decrease without a subsequent transient increase. A reported minimal length of 
prolonged luteal activity is 30 days from ovulation to a decrease of P4 to < 1 ng/mL [31]. 
Pulses of PGFM were identified on each of Days 14 to 16 in an 8-hour set of hourly 
blood samples. To distinguish between fluctuations and pulses, the intra-assay coefficient of 
variation (CV) was used as described [34]. Briefly, a PGFM fluctuation was an increase and 
decrease encompassing at least four hourly values, including nadirs. A fluctuation with a CV 
that was at least three times greater than the mean intra-assay CV was defined as a pulse. The 
peak of an identified PGFM pulse was designated as 0 hour.   
 
 
 
71 
 
 
3.2.3. Hormone assays 
 
Blood samples were immediately placed in ice water for 10 min after collection, 
followed by centrifugation (2,000 X g for 10 min). The plasma was decanted and stored (–20º 
C) until assayed. Plasma samples were assayed for PGFM by an ELISA that was developed 
and validated in our laboratory for use in mare plasma [6]. Plasma P4 concentrations were 
determined with a solid-phase RIA kit containing antibody-coated tubes and 125I-labeled P4 
(Coat-A-Count Progesterone, Diagnostic Products Corporation, Los Angeles, CA, USA). The 
procedure has been validated and described for mare plasma in our laboratory [35]. Plasma 
concentrations of estradiol-17β were measured by a double-antibody radioimmunoassay kit 
(Double Antibody Estradiol, Diagnostic Products Corporation, Los Angeles, CA, USA), as 
described and validated in our laboratory for mare plasma [36]. The intra- and interassay CV 
and sensitivity, respectively, were 12.8%, 19.0%, and 4.1 pg/mL for PGFM and 8.3%, 4.7%, 
and 0.03 ng/mL for P4. The intra-assay CV and sensitivity for estradiol were 5.7% and 0.78 
pg/mL, respectively. 
 
3.2.4. Statistical analyses 
 
 Data were examined for normality using the Shapiro-Wilk test. Data that were not 
normally distributed were transformed to natural logarithms or ranks. Statistical outliers (P < 
0.05) for intervals were determined by the Dixon test. Determination was made of the main 
effects of group and time (daily, 8-hour intervals, and hourly) and the interaction of group and 
time. An inadequate number of PGFM pulses on Days 14 (n = 1) and 15 (n = 0) in the FM 
group was managed by partitioning the mares into day/group combinations of Day 14/control, 
Day 15/control, Day 16/control, and Day 16/FM. The six day/group combinations were also 
used in the analyses of PGFM and P4 for the 8-hour sets of hourly samples each day. The 
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statistical analyses were done by using SAS PROC MIXED (Version 9.2; SAS Institute Inc., 
Cary, NC, USA). Owing to repeated measures in each mare, a repeated statement was used to 
account for autocorrelation by modeling the first-order autoregressive or spatial power between 
sequential measurements. Student’s unpaired t-tests were used for comparing differences 
between the control and FM groups at each examination, and Student’s paired t-tests were used 
to compare times within a group. Discrete characteristics between groups were compared by 
Student’s unpaired t-tests. A probability of P ≤ 0.05 indicated that a difference was significant, 
and a probability of P > 0.05 to ≤ 0.10 indicated that significance was approached. Data are 
presented as the mean ± SEM, unless otherwise indicated. 
 
3.3. Results 
 
Two mares in the control group and two in the FM group were omitted from the 
analyses. Luteolysis in these four mares was complete (P4 < 1 ng/mL) or underway (P4 1.7 to 
3.4 ng/mL) before the first treatment on Day 14. The remaining mares (n = 6/group) were in 
preluteolysis and were used in the analyses. The probabilities for a main effect of group or a 
day/group combination and time (daily, 8-hour intervals, hourly) and the interaction for 
differences that were significant or approached significance are shown in the figures or tables. 
Other probabilities for differences are given in the text. 
Daily concentrations of PGFM had only a day effect that approached significance 
primarily from greater concentration averaged over groups for Day 16 than for Day 14 (Fig. 
3.2). The percentage change from Day 11 was used for P4, CL area, and endometrial score 
because of apparent differences between the two groups for the 3 days before the first treatment. 
Significant day effects averaged over groups represented decreases after Day 14 in percentage 
change in P4 concentration and CL area and in percentage of CL with blood-flow signals. 
Significant day effects representing increases after Day 14 were obtained for estradiol 
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concentration and percentage change in endometrial score. Although only a day effect was 
significant for percentage change in CL area and percentage change in endometrial score, days 
of a difference (P < 0.05) between groups are shown (Fig. 3.2). A group effect that approached 
significance for percentage change in P4 concentration and percentage of CL with blood-flow 
signals reflected greater values in the FM group averaged over Days 14 to 21 for P4 and for 
blood flow. Days of a difference (P < 0.05) between groups are shown (Fig. 3.2). 
Concentrations of PGFM at 8-hour intervals on Days 13.0 to 17.0 had only a day effect 
(Fig. 3.3). Concentrations were greater (P < 0.05) averaged over the two groups on Days 15.0, 
15.3, 16.3, and 16.7 than on Day 14.0. Percentage change in P4 concentrations had significant 
effects of group and day and an interaction that approached significance. The interaction was 
represented by greater (P < 0.05) concentration in the FM group than in the controls on each 
of Days 14.7 to 17.0; there was an approaching greater (P < 0.09) concentration on Day 14.3. 
These differences accounted for the group effect. 
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Figure 3.2. Mean ± SEM concentrations of PGFM; percentage change from Day 11 in 
concentration of progesterone (P4), endometrial score (1 to 4 for increasing edema), and cross-
sectional area of the CL; concentrations of estradiol; and percentage of CL with color-Doppler 
signals of blood flow from Days 11 to 21 in controls and flunixin meglumine (FM) treated 
mares (1.0 mg/kg). Arrow with broken line indicates first treatment and the rectangle indicates 
the period of treatment (every 8 hours). Probabilities for main effects of group (G) and day (D) 
and the interaction (GD) are shown. An asterisk (*) indicates a day with a difference between 
groups (P ≤  0.05). 
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Figure 3.3. Mean ± SEM concentration of PGFM and percentage change from Day 13.0 in 
progesterone (P4) every 8 hours from Days 13.0 to 17.0. The arrows indicate that flunixin 
meglumine (FM, 1.0 mg/kg) was given every 8 hours from Day 14.0 to 16.7. Probabilities for 
main effects of group (G) and day (D) and the interaction (GD) are shown. An asterisk (*) 
indicates a day with a difference between groups (P ≤ 0.05). 
 
Concentrations of PGFM at hourly intervals for Hours 0 to 8 had significant day/group 
combination and hour effects and an interaction of combination and hour that approached 
significance (Fig. 3.4). The combination effect represented progressively greater 
concentrations averaged over hours within each of the six day/group combinations and greater 
concentrations in the control group than in the FM group averaged within each day as shown 
(Table 3.1). The interaction represented differences among the six combinations of group and 
day as shown (Fig. 3.4). Concentration was lower (P < 0.05) in the FM group than in the 
controls at Hours 2, 3, 5, and 6 on Day 14 and at Hours 3 to 5 on Days 15 and 16. Other 
differences among the six combinations of days and groups were complex and are shown (Fig. 
3.4). Concentrations of P4 at hourly intervals for Hours 0 to 8 had significant main effects of 
combination and hour without an interaction (Fig. 3.4). The changes within each combination 
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for the 3 days and between groups within each day were in the opposite direction to the changes 
for PGFM as shown (Table 3.1). When the two groups were compared within each day, the 
hour effect averaged over groups was significant from a decrease over hours for Day 15 (P < 
0.01) and for Day 16 (P < 0.0001); there was no interaction for either day.  
 
Table 3.1. Mean ± SEM for PGFM and P4 concentrations averaged over 8 hours of hourly 
blood sampling on each of Days 14 to 16 for the control and FM groups. 
Day Control group FM group Probability 
PGFM (pg/mL) 
   
14 13.8 ± 2.9a 6.7 ± 1.3a P < 0.05 
15 35.2 ± 10.4ab 15.0 ± 3.9ab P < 0.10 
16 54.7 ± 11.4b 21.9 ± 5.7b P < 0.03 
P4 (ng/mL)    
14 7.7 ± 0.9x 10.1 ± 0.9x P < 0.08 
15 4.3 ± 1.0y 9.2 ± 1.0xy P < 0.008 
16 1.2 ± 0.4z 5.6 ± 1.6y P < 0.02 
                                             
ab Means for PGFM within the control group or within the FM group with no common 
superscript letters are different (P <0.05). 
xyz Means for P4 within the control group and within the FM group with no common 
superscript  letters are different (P < 0.05). 
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Figure 3.4. Mean ± SEM concentrations of PGFM and progesterone (P4) at hourly intervals 
for 8-hour sets at the beginning of each of 3 days for the controls and flunixin meglumine (FM) 
treated groups, using six combinations of day and group as shown. The PGFM concentrations 
are in two different scales on the y-axis. Probabilities for a main effect of combination (C) and 
hour (H) and the interaction (CH) are shown. Within each hour, means without a common letter 
(abcd) are different (P < 0.05). 
 
In the Day 14/FM and Day 15/FM combinations, only one and no mares, respectively, 
had a detected PGFM pulse during the 8 hours of hourly samples, and these two combinations 
were not included in the analyses of pulses. In the remaining four combinations, the mean 
number of pulses per 8 hours was not different among combinations (Table 3.2). In addition to 
the expected hour effect when pulses were normalized to the peak, the main effect of the 
day/group combination was also significant (Fig. 3.5). The combination effect was represented 
by greater (P < 0.05) average PGFM concentration in the Day 16/control than in the Day 
14/control and Day 16/FM combinations (Table 3.2). Concentration was greater (P < 0.05) at 
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the peak (0 hour) and the hour before the peak in the Day 16/control than in the Day 14/control 
and Day 16/FM combinations (Fig. 3.5). The amplitude of the PGFM pulses was greater (P < 
0.05) in the Day 16/control than in the Day 14/control and the Day 16/FM combinations (Table 
3.2). There were no differences among the four combinations for concentration at the nadirs or 
the interval from beginning to ending nadirs of the PGFM pulse. An apparent (P < 0.1) gradual 
decline in concentration of P4 occurred within the hours of a PGFM pulse in the Day 15/control 
and Day 16/control combinations but not in the other two combinations (not shown). 
 
Table 3.2. Mean ± SEM concentrations of PGFM in detected PGFM pulses during 8 hours of 
hourly sampling on the indicated days postovulation in mares in the control and FM groups. 
Pulse characteristics 
Control group  FM group Proba- 
bility Day 14 Day 15 Day 16 
 
Day 16 
Number pulses/mare/8 hours 0.7 ± 0.2 0.8 ± 0.2 0.8 ± 0.2  0.7 ± 0.2 NS 
Peak (pg/mL) 23.0 ± 6.8a 85.2 ± 28.2b 136.8 ± 33.1b  36.0 ± 7.7a P < 0.02 
Nadir 1 (pg/mL) 8.4 ± 1.8 30.0 ± 24.3 29.6 ± 7.2  18.9 ± 6.9 NS 
Nadir 2 (pg/mL) 15.8 ± 8.6 16.3 ± 4.3 25.2 ± 5.3  11.0 ± 0.8 NS 
Amplitude (pg/mL) 14.7 ± 5.3a 55.3 ± 22.7ab 107.2 ± 37.3b  17.1 ± 5.3a P < 0.06 
Mean for all hours 15.4 ± 4.6a 37.8 ± 13.0ab 65.6 ± 11.8b  18.8 ± 4.1a P < 0.01 
Pulse duration (hours) 4.8 ± 0.2 6.6 ± 0.9 6.4 ± 0.8  5.5 ± 0.9 NS 
 
There was only 1 or 0 mares with a PGFM pulse during the 8 hours of hourly sampling in the 
Day 14/FM and Day 15/FM day/group combinations, respectively.  
NS = Neither significant nor approaching significance. 
 
 
79 
 
 
 
Figure 3.5. Mean ± SEM concentrations of PGFM in identified pulses centered on the pulse 
peak for four combinations of day and group. Only one and zero pulses were detected in the 
FM group on Days 14 and 15, respectively, and were not included. Probabilities for a main 
effect of combination (C) and hour (H) and the interaction (CH) are shown. Within each hour, 
any two means without a common letter (abc) are different (P < 0.05).  
  
 In the FM group, the interval from ovulation to the beginning of luteolysis was a 
statistical outlier in one mare (21 days; IOI, 28 days) and the interval from ovulation to the end 
of luteolysis was an outlier in another mare (36 days; IOI, 41 days). These two intervals were 
used to indicate the occurrence of prolonged luteal activity, and the intervals, but not the PGFM 
and P4 concentrations, were omitted from the analyses between groups. The mare with an IOI 
of 41 days had a transient decrease in P4 on an expected day of luteolysis (Fig. 3.6). 
Concentrations decreased to 1.3 ng/mL on Day 18 and then increased to > 4 ng/mL. Changes 
in cross-sectional area of the CL and percentage of CL with blood-flow signals were similar to 
the P4 concentration change. The interval from ovulation to the beginning of a progressive and 
continuous decrease in P4, as determined by averaging data for individuals, and from ovulation 
to the end of the luteal phase (P4 < 1 ng/mL) were longer in the FM group than in the controls 
(Table 3.3). The mean beginning of a decrease in P4 concentration based on inspection of 
figures was Days 14 and 15 for the daily samples (Fig. 3.2) in the control and FM groups, 
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respectively, and Days 14.3 and 15.3 for the 8-hour samples (Fig. 3.3). The first significant 
decrease in percentage change in P4 from Day 14.0 in the samples at 8-hour intervals occurred 
on Day 15.0 in the controls and Day 16.0 in the FM group. The interval from the end of the 
luteal phase to ovulation was not different between groups (Table 3.3).  
 
Table 3.3. Mean ± SEM length of intervals (days) between events in control and FM  
groups, based on an 8-hour interval between blood samples. 
 
Interval (days) 
Control group 
(n = 6) 
FM group 
(n = 5)a Probability 
Interovulatory (IOI) 23.3 ± 0.7 24.8 ± 9.7 NS 
Ovulation to beginning of P4 
decrease 14.4 ± 0.1 15.3 ± 0.4 P < 0.03 
Ovulation to P4 < 1 ng/mL 16.1 ± 0.2 18.3 ± 0.9 P < 0.02 
P4 < 1 ng/mL to ovulation 7.3 ± 0.6 6.3 ± 0.6 NS 
 
a A statistical outlier was omitted for the IOI and for intervals from ovulation to the beginning 
of a P4 decrease and to a P4 concentration < 1 ng/mL. 
NS = Neither significant nor approaching significance. 
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Figure 3.6. Concentrations of progesterone (P4) and PGFM, cross-sectional area of the CL, 
and percentage of CL with color-Doppler signals of blood flow for an individual mare in the 
flunixin meglumine group that had prolonged luteal activity and IOI. A transient decrease in 
P4 began on Day 15, did not decrease to < 1 ng/mL, and then increased beginning on Day 19. 
A maximal concentration of PGFM occurred near the beginning of the initial transient decrease 
and the final decrease in P4 near the end of the 41-day IOI. The profile for area of the CL (cm2) 
and percentage of the CL area with blood-flow signals approximated the profile for P4 
concentrations. Study by ultrasonic imaging seemed to indicate that a single CL was involved. 
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3.4. Discussion 
 
3.4.1. Inhibition of PGFM 
 
Treatment with FM during the expected luteolytic period (Days 14 to 16) in mares 
inhibited the secretion of PGF2α, as indicated by a metabolite (PGFM) and as previously 
reported for cattle [16] and sheep [37]. In heifers, three treatments with FM at 8-hour intervals 
during preluteolysis (Day 16) effectively inhibited PGF2α for about 24 hours from first 
treatment [16]. Similar results were obtained in the current study in mares, except that each FM 
treatment at 8-hour intervals was effective for only 7 hours. This was indicated by a return to 
approximately the concentration in controls between Hours 7 to 8 on Days 15 and 16. There 
was no indication that the 1-hour lapse in PGF2α suppression resulted in a change in P4 
concentration at the end of each 8-hour set of hourly sampling. That is, the PGFM was reduced 
from the low concentration in controls on Day 14 and from the greater concentration in controls 
on Days 15 and 16.  
Collection of blood samples at 1-day or 8-hour intervals was ineffective in 
demonstrating the FM-induced reduction in PGF2α concentration. The increase in PGFM, 
especially after Day 15 (day effect) likely reflected an increase in prominence of PGFM pulses 
and the chance occurrence of sampling during a major portion of a pulse in individuals. The 
day effect was demonstrated effectively by using the average for the hourly samples in the 8-
hour set for each day. 
The increase in prominence of the PGFM pulses increased over days as indicated by 
peak concentration, amplitude, and overall mean concentration, agrees with the report [6] that 
the prominence of PGFM pulses increases from preluteolysis to postluteolysis. The 
effectiveness of FM in reducing the number of PGFM pulses on Days 14 and 15 was shown by 
the detection of one pulse in only one mare and on only one day. Although the number of pulses 
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in the FM-treated group on Day 16 was similar to the number in the controls on each of Days 
14 to 16, the prominence of the Day-16 pulses in the treated group was low. The PGFM pulses 
in the controls on Days 14 to 16 and the pulses in FM-treated mares on Day 16 originated from 
a base that was similar among days, as indicated by the similarity between groups and among 
days in the concentrations at the nadirs and in duration of the base of the pulse. 
The effectiveness of FM treatment in reducing the PGFM concentration on each of 
Days 14, 15, and 16 was indicated by the lower concentration averaged over the 8-hour sets of 
hourly sampling at the beginning of each day. The mean concentration in the FM-treated mares 
was 48%, 43%, and 40% of the concentration in the controls on Days 14, 15, and 16, 
respectively. The mean concentration increased progressively over Days 14 to 16, in both the 
controls and FM-treated group. The percentage increase in the controls between Days 14 and 
15 (39%) and between Days 15 and 16 (64%) seemed similar to the corresponding percentage 
increase in the FM group (48% and 68%). The similarity between groups in the percentage 
change in PGFM concentrations among days indicated similar effectiveness of the FM over 
Days 14 to 16. In contrast, the presence of only one mare with a PGFM pulse on Day 14 and 
the absence of pulses on Day 15 in the FM group and a similar number in the controls and FM 
group on Day 16 indicated a loss of FM effectiveness on Day 16. However, the pulses were 
considerably less prominent on Day 16 in the FM group than on Day 16 in the controls. The 
relative effectiveness of FM on different days cannot be adequately assessed for the current 
study because of the continuous treatment over days. Further study would be needed that 
includes treatment that is limited to each day. 
 
3.4.2. Progesterone response to inhibiting PGF2α 
 
Hypothesis 1, that inhibition of PGF2α synthesis interferes with luteolysis, was 
supported. Support was from the following: (1) an approaching group effect for P4 in the daily 
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samples, with greater concentration (represented by percentage change) in the FM group during 
Days 15 to 18; (2) a group effect and approaching interaction for P4 in the samples collected 
every 8 hours, with greater concentration in the FM group on Days 14.7 to 17.0; (3) greater 
concentration of P4 in the FM group averaged over the hourly samples for each of Days 15 and 
16; and (4) longer intervals from ovulation to the beginning and to the end of luteolysis in the 
FM group. The analyses for PGFM and P4 used all 12 mares, but the analyses for length of 
intervals did not include the outliers for the beginning and for the end of luteolysis. If the 
outliers had been included, the mean lengths would have been even longer in the FM group. 
After excluding the outliers, the beginning of luteolysis and the end of luteolysis were each 
delayed approximately 1 day by FM treatment that began before the end of the preluteolytic 
period, based on the samples collected every day or every 8 hours. The similar 1-day delay in 
the beginning and in the end of luteolysis and the approximately parallel decrease in P4 
between groups on Days 15.3 to 17.0 indicated that the effect of the reduction in PGF2α was 
exerted at the beginning of luteolysis, rather than during the later portion of luteolysis. These 
results were unexpected but suggest that PGF2α exerts its major effect at the initiation of 
luteolysis, and this could serve as rationale for further studies. This is apparently the first 
demonstration in mares that inhibiting PGF2α interferes with luteolysis. The longer IOI in the 
FM group was attributable to the longer luteal phase in that the interval from the end of 
luteolysis to the end of the IOI was not different between groups 
Luteolysis or the period of decreasing P4 encompassed several days in the controls and 
in the FM group when outliers were included and daily samples were used. A luteolytic period 
of 2 to 4 days has been reported for daily samples in nontreated mares [7,38]. The prolonged 
period of luteolysis for daily samples and samples collected every 8 hours is illusionary, 
however, owing to the beginning of luteolysis on different days in individuals [7]. Based on 
hourly sampling, the length of luteolysis in mares is 23 hours rather than several days [6,7]. 
Critical study involving frequent blood sampling (e.g., hourly) is needed, especially for detailed 
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study on the beginning of luteolysis. The current study with daily sampling provides guidance 
on when to do the frequent sampling. 
 
3.4.3. Prolonged luteal activity 
 
Hypothesis 2, that inhibition of PGF2α at the expected time of luteolysis may lead to 
prolonged luteal activity, was supported. The support was from two mares in the FM group 
that met the definition of prolonged luteal activity on the basis of statistical outliers involving 
the luteal phase. Reservation is indicated, however, because the small number of mares in each 
group (n = 6) precluded an analysis on a difference in frequency of prolonged luteal activity 
between the two groups. In addition, the prolonged luteal activity (21 and 36 days) was shorter 
than for other reports [27,30].  
The mare with a 21-day interval from ovulation to the beginning of luteolysis and a 28-
day IOI was deficient in PGFM and was the only mare in either group with PGFM 
concentrations that were at assay sensitivity for all samples from Day 11.0 to Day 17.3. The 
role of FM in the continuation of the low PGFM concentrations in this mare cannot be 
determined in that the low concentrations also occurred for all six samples collected before 
treatment. In the mare with the 36-day interval to the end of luteolysis and a 41-day IOI, an 
increase in PGFM and the beginning of a P4 decrease occurred at the expected time on Day 
15, based on daily samples. A pulse of PGFM was not detected during hourly sampling on 
Days 14 to 16. The P4 decreased to 1.3 ng/mL by Day 19, but an immediate increase or 
resurgence prevented designating the day of the end of luteolysis (Fig. 3.6). Area of the CL and 
percentage of CL with blood-flow signals followed the P4 profile. Although not commented 
upon, a similar transient decrease in P4 on approximately the day of the expected end of 
luteolysis followed by resurgence is apparent in published P4 profiles in several of 12 cases of 
spontaneous prolonged luteal activity in nonbred Thoroughbred mares [30]. Ovulation was not 
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detected near the current and reported transient depressions in P4 concentrations. In the current 
study, the CL before and after the transient P4 depression to almost 1 ng/mL was apparently 
the same structure. The structure was in the same location in the ovary each day, and the largest 
follicle combined for both ovaries was 16.2 mm on the days before and during the resurgence 
(Days 17 to 19), compared to a preovulatory follicle diameter of ~ 45 mm [2]. Luteinization of 
a follicle in the same area of the ovary seems unlikely but cannot be ruled out.  
Resurgence of P4 concentrations has been reported previously under several conditions. 
Apparent partial resurgence of the CL from the previous estrous cycle after P4 decreased to < 
1 ng/mL has been reported during early pregnancy in a pony [39]. The resurgence was indicated 
by an increase in cross-sectional area of the CL from the previous cycle and by an increase in 
P4 that reached unusually high concentrations on approximately Days 5 to 10 of pregnancy. In 
both ponies and horses, the size of the primary CL and P4 concentrations resurge after Day 30 
of pregnancy [39,40]. Treatment of mares with a low dose (0.5 mg) of PGF2α results in P4 
resurgence, but not when a second treatment is given the next day [41]. Resurgence in P4 
concentration occurs when mares are treated with a single 5-mg dose of PGF2α on Days 2 or 
3 [42]. Resurgence was reported in three heifers in association with a nonprominent PGFM 
pulse [43]. It is not known if the resurgence of the CL involves an increase in number of luteal 
cells or an increase in size of the extant luteal cells. In this regard, the small luteal cells may 
differentiate into large luteal cells [44] under the influence of LH [45]. Further study is needed 
to confirm that resurgence after luteolysis nears completion is a phenomenon that may occur 
naturally. 
 The mechanism involved in spontaneous or idiopathic prolonged luteal activity is not 
known, but impaired PGF2α secretion has been suspected [27,29,30,46]. Previous studies with 
a prolonged luteal phase induced by altrenogest treatment indicated that mares with prolonged 
luteal activity had a lower response to oxytocin treatment compared to controls, perhaps from 
inadequate oxytocin receptors in the endometrium [47]. The mechanism may be similar to that 
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described for pregnant mares, wherein concentrations of oxytocin receptors are considerably 
lower in pregnant than in cycling mares [48]. Paradoxically, repeated administration of 
oxytocin during diestrus in the mare prolongs luteal function [49,50]. Speculatively, the 
syndrome of prolonged luteal activity may involve low numbers of oxytocin receptors, and the 
prolonged luteal activity associated with chronic oxytocin treatment may involve down-
regulation or saturation of the oxytocin receptors. The mechanism that leads to the prolonged 
luteal activity syndrome and the potential role of oxytocin needs to be studied. 
 
3.5. Conclusions 
 
 Secretion of PGF2α is needed for luteolysis in mares, based on a 1-day delay in both 
the beginning and end of luteolysis in association with inhibition of PGF2α by FM. An increase 
(statistical outliers) in the length of the luteal phase may occur (2 of 6 mares) after inhibition 
of PGF2α secretion on Days 14.0 to 16.7. One of the mares with prolonged luteal activity had 
a transient decrease in P4 on the expected days of luteolysis, but a resurgence in P4 
concentration occurred before P4 decreased to < 1 ng/mL. 
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Abstract 
 
Mares with persistent corpus luteum (PCL) with no known etiology (idiopathic) were 
matched with mares with an interovulatory interval (IOI) of apparent physiologic length, so 
that ovulation at the beginning of each PCL and IOI occurred during the same month (n = 6 
/group). Blood samples were collected daily from Days 12 to 22 (Day 0 = ovulation). Mean 
progesterone (P4) decreased in both groups on Days 14 and 15 and then diverged with a 
continued decrease in the IOI group and the beginning of constant and greater (P < 0.05) P4 
concentration on each day in the PCL group. Before P4 divergence between groups, P4 in the 
PCL group decreased either abruptly (apparent incomplete luteolysis) or gradually. 
Concentration of PGFM (a metabolite of PGF2α) was not different between groups and reached 
maximum on mean Day 15 in each group. After the divergence in P4 between groups, LH and 
estradiol (E2) remained low in the PCL group. There was no indication that an increase in a 
luteotropic effect of LH in the PCL group accounted for the divergence in P4. Differences in 
prolactin between groups were inconclusive. The hypothesis that secretion of PGF2α at the 
time of expected luteolysis is defective in mares with idiopathic PCL was not supported. The 
hypothesis that E2 concentration before expected luteolysis is greater in mares with PCL than 
without PCL was not supported; however, a difference on Day 12 approached significance (P 
< 0.06) and tentatively indicated greater E2 in the PCL group before the beginning of luteolysis.  
 
Keywords: Corpus luteum; Estradiol; Persistent CL; PGF2α; Progesterone; 
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4.1. Introduction 
 
The corpus luteum (CL) is a transient endocrine gland essential to the establishment 
and maintenance of pregnancy by progesterone (P4) production (mare reviews [1–5]). 
Functional and structural regression or luteolysis of the CL occurs in the absence of a viable 
embryo. In the mare, luteolysis begins on average on Day 14 (Day 0 = ovulation) and based on 
hourly blood sampling lasts 23 hours [6]. In many species, including mares, CL regression 
utilizes multiple pulses of prostaglandin F2α (PGF2α) that are secreted by the nongravid uterus 
[7]. Circulating concentrations of a PGF2α metabolite (PGFM) is often used to represent 
changes in PGF2α concentrations [8], owing to the short half-life of PGF2α [9]. The base of a 
PGFM pulse from nadir to nadir is about 5 h in mares, and the peak of sequential pulses occurs 
about every 9 h [7]. 
A CL that fails to regress during the expected time of luteolysis in a nonpregnant mare 
is termed persistent CL (PCL) [10,11]. The condition is reported to occur in 8 to 10% of estrous 
cycles during the peak of the ovulatory season and about 25% during the autumn months [11]. 
Persistent CL can be related to ovulation late in diestrus, embryonic loss after the first luteal 
response to pregnancy, and uterine pathology such as pyometra (reviews [1,10,12,13–14]). The 
term uteropathic PCL is appropriate when the condition can be attributed to a uterine 
abnormality or pathology [10]. However, PCL also occurs without any known etiology and has 
been named idiopathic PCL [10] or spontaneous PCL [11,15]. Idiopathic or spontaneous can 
be replaced by an appropriate term when a specific nonuterine cause becomes known. 
Length of the luteal phase as indicated by continued secretion of P4 is prolonged about 
2 mo in mares with PCL [15,16]. Sequential mean P4 concentration for multiple mares with 
PCL and a statistical comparison of P4 concentrations between mares with and without PCL 
are limited. However, P4 profiles in individual mares with PCL have been published [15–18]. 
Based on individual profiles, Stabenfeldt and coworkers [15] stated, “… progestin levels in 
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mares with prolonged luteal activity follow the characteristic pattern for normal animals until 
about day 13 or 14 postovulation…followed by a plateauing of progestin levels around 4 to 5 
ng/ml plasma”. 
The secretion of PGF2α was initially reported to be the luteolytic factor in mares based 
on termination of diestrus following administration [19] and by PGF concentrations in the 
uterine vein of nonpregnant versus pregnant mares [20]. The luteolytic role of PGF2α in mares 
has been confirmed (reviews [21,22]). Idiopathic PCL has been attributed to failure of PGF2α 
secretion at the appropriate time [11,17]. However, for each of these reports the conclusion that 
idiopathic PCL results from a failure of PGF2α secretion apparently was based on an individual 
mare. Inhibition of PGF2α secretion at the time of expected luteolysis prolonged the luteal 
phase (P4 > 1 ng/mL) but only for 21 and 36 days in two of eight mares (statistical outliers) 
[23]. In addition, one of the mares had a history of 5/21 (31%) ovulations that were followed 
by PCL (unpublished). Clearly, the involvement of defective PGF2α secretion in idiopathic 
PCL has not been critically established. The uterus does not lose the ability to secrete or the 
CL to respond to PGF2α as demonstrated by the termination of PCL after an increase in PGF2α 
concentration from intrauterine infusion of saline [11,17].  
Ovulation sometimes occurs during PCL [16,24], but full estrous behavior does not 
[16,25]. The follicular wave in PCL that corresponds to the ovulatory follicular wave in an 
interovulatory interval (IOI) in mares has not been characterized. In one mare with PCL, a 
small follicle was detected by transrectal palpation at the end of diestrus but then regressed and 
no other follicles were detected [16]. Another report indicated that follicular growth was 
initiated before Day 14 during an IOI and at mean Day 19 during spontaneously prolonged 
cycles [26]. Individual profiles for P4, LH, and estradiol (E2) for PCL have been described in 
two mares [16]. Concentrations of E2 fluctuated widely from day to day, and in one mare the 
high LH concentrations associated with estrus appeared to remain high during a portion of the 
PCL. In another study, mean urinary estrogen concentration was greater during Days 5 to 10 
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in mares that developed PCL than in mares that did not. [25]. Concentration of E2 were also 
reported to be similar between the early luteal phase and the expected time of luteolysis in 
mares with PCL, contrasting with an increase in E2 between the two luteal phases in IOIs [26]. 
Prolactin increases during luteolysis during the IOI and during the expected time of luteolysis 
in mares with PCL [11]. However, a role for prolactin in PCL should be further considered, 
owing to the demonstrations that prolactin in mares is involved in reproductive seasonality 
[18], prolactin activity increases during luteolysis [27], pulses of prolactin and PGFM are 
synchronized [27,28], and PGF2α stimulates prolactin rather than prolactin stimulating PGF2α 
[29]. 
Studies on circulating hormone concentrations in mares with PCL have considered 
hormone profiles in individual mares with PCL, usually without comparison to mares without 
PCL. Concentration of LH has been reported only for individuals and characterization of 
follicular waves, cross-sectional area of the CL, and the extent of blood flow in the CL have 
not been considered. 
The current study compared mares with and without idiopathic PCL, using daily 
concentrations of P4, PGFM, E2, LH, and prolactin beginning on Day 12 until Day 22 so that 
the period of luteolysis in mares without PCL would be encompassed. In addition, luteal 
dimensions and blood flow and the characteristics of the dominant follicle were included. The 
hypotheses were (1) secretion of PGF2α at the time of expected luteolysis is defective in mares 
with idiopathic PCL and (2) E2 concentration before expected luteolysis is greater in mares 
with PCL than without PCL. Rationale was not adequate for hypothesizing whether a 
luteotropic factor was involved in PCL. 
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4.2. Materials and methods 
 
4.2.1. Mares 
  
Nonlactating mares of unknown breeding, aged 4 to 14 y, and weighing 360 to 520 kg 
were used in the northern temperate zone. The wide range of weight and body conformation 
indicated an individual mare could be described as a horse or a pony-horse cross. Abnormalities 
of the reproductive tract were not detected by transrectal ultrasonic scanning [30]. The mares 
had not been bred for at least 3 y. The ovulation at the beginning of an IOI or PCL occurred 
during September to October, 2012 and May to July, 2013. Mares were housed in an open 
shelter and outdoor paddock and were maintained by free access to primarily grass hay, trace-
mineralized salt, and water. The mares were housed under natural light during spring, summer, 
and fall (April through November in the northern hemisphere) and under artificially extended 
photoperiod during the winter (December through March) as described [1]. All mares remained 
healthy and in good body condition throughout the study. Mares were handled according to the 
United States Department of Agriculture Guide for Care and Use of Agricultural Animals in 
Agricultural Research and Teaching. 
 
4.2.2. Protocol 
 
Mares were examined daily by transrectal ultrasound with a duplex B-mode (gray scale) 
and color-Doppler ultrasound scanner (Aloka SSD 3500; Aloka American, Wallingford, CT, 
USA) equipped with a linear-array 7.5 MHz transducer. The scanner was used for determining 
the day of ovulation, luteal area (cm2) at the maximal cross-sectional plane, percentage of CL 
with power-Doppler signals for blood flow [31], diameter of largest follicle, and endometrial 
score. The percentage of CL with power-Doppler signals of blood flow was estimated from a 
100 
 
scan of the entire CL as described and validated [31]. The endometrial score (1 to 4, minimal 
to maximal) was based on anechoic areas as indicators of the extent of endometrial edema 
[30,32]. 
Mares in a PCL group (n = 6) were selected that had continuation of the luteal phase 
until the end of experiment on Day 28, as indicated by daily determination of CL area (cm2), 
percentage of CL with Doppler blood-flow signals, and circulating concentration of P4. An IOI 
group (n = 6) was randomly selected with the beginning of the IOI in the same month as the 
ovulation at the beginning of each PCL. Comparisons were made on Days 12 to 22 between 
the IOI group and PCL group for concentrations of P4, PGFM, LH, and prolactin; Days 12 to 
20 for E2; and Days 11 to 22 for diameter of the largest follicle, area (cm2) and blood-flow 
signals of the CL, and endometrial edema. Statistical comparisons between groups ended on 
Day 22 in that the ending ovulation in the IOI group occurred on or after Day 22 in five IOIs 
and on Day 18 in the remaining IOI. Data for the PCL group were shown until Day 28. 
 
4.2.3. Hormone assays 
 
Blood samples were collected into heparinized vacutainer tubes by venipuncture of a 
jugular vein. Samples were immediately placed in ice water for 10 min, followed by 
centrifugation (2,000 X g for 10 min). The plasma was decanted and stored (–20 ºC) until 
assayed. The assay procedure for each hormone or factor has been validated and described for 
mare plasma in our laboratory as indicated. Plasma samples were assayed for P4 by a solid-
phase RIA kit containing antibody-coated tubes and 125I-labeled P4 (Coat-A-Count 
Progesterone, Diagnostic Products Corporation, Los Angeles, CA, USA) [33]. The intra- and 
interassay CV and sensitivity for P4 were 6.4%, 8.2%, and 0.02 ng/mL, respectively. Plasma 
samples were assayed for PGFM by an ELISA [6]. The intra- and interassay CV and sensitivity 
were 8.9%, 10.1%, and 4.8 pg/mL, respectively. Plasma concentrations of LH were determined 
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by RIA [34]. The intra-assay CV and sensitivity were 4.8% and 0.2 ng/mL, respectively. The 
concentrations of E2 were measured by a double-antibody RIA kit (Double Antibody Estradiol, 
Diagnostic Products Corporation) [34]. The intra-assay CV and sensitivity were 9.6% and 0.08 
pg/mL, respectively. Plasma samples were assayed for prolactin by RIA [34]. The intra-assay 
CV and sensitivity were 8.7% and 0.3 ng/mL, respectively. 
 
4.2.4. Statistical analyses 
 
Data were examined for normality using the Shapiro-Wilk test. Data that were not 
normally distributed were resolved by transformation to natural logarithms or ranks. A value 
defined as an extreme outlier within both a day and within an animal by the interquartile range 
analysis was removed from the analyses and figures. The statistical analyses were done by 
using SAS PROC MIXED (version 9.3; SAS Institute Inc., Cary, NC, USA). A repeated 
statement was used to account for autocorrelation by modeling the first-order autoregressive 
between sequential measurements. Determination was made of the main effects of group and 
day and the interaction of group and day. When a significant interaction was found, student’s 
unpaired t-tests were used for comparing differences between IOI and PCL groups within a 
day. A probability of P ≤ 0.05 indicated that a difference was significant and a probability of P 
> 0.05 to ≤ 0.10 indicated that significance was approached. Differences that approached 
significance were included on a preliminary basis for potential consideration in future studies. 
Data are presented as the mean ± SEM, unless otherwise indicated. 
 
4.3. Results 
 
Daily concentration of P4 had significant main effects of group and day and a group-
by-day interaction (Fig. 4.1). The group effect was from greater concentration of P4 averaged 
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over Days 12 to 22 in the PCL group (8.9 ± 0.6 ng/mL) than in the IOI group (3.3 ± 0.7 ng/mL). 
The group-by-day interaction was represented by no differences in P4 between groups on Days 
12 to 14 and greater concentration in the PCL group on Days 15 to 22. Concentration of P4 
decreased until the end of luteolysis (P4 < 1 ng/mL [15]) on Day 16 in the IOI group, whereas 
P4 concentration did not differ during Days 15 to 28 in the PCL group. On Days 15 to 22, P4 
concentration in the PCL group in individuals was 46 to 54% of the concentration on Day 12. 
Concentration of P4 in individual mares in the IOI and PCL groups is shown (Fig. 4.2). A 
pronounced 1-day decrease in P4 was apparent in each IOI mare beginning on Day 13, 14, or 
15. In two mares in the PCL group, an abrupt 1-day decrease in P4 occurred similar to the 
decrease at the beginning of luteolysis in the IOI group. In three mares, the P4 decrease was 
gradual from Day 12 or 13 to Day 16 or 17. In the other mare, the P4 decrease fluctuated and 
did not fit adequately into either subgroup. 
Concentration of PGFM had an effect of day from increases and decreases averaged 
over groups with the maximal concentration in each group on Day 15 (Fig. 4.1). The group 
effect, interaction, and maximal concentration were not significantly different and did not 
approach significance between groups.  
Concentration of E2 had an effect of day and a group-by-day interaction (Fig. 4.1). The 
group-by-day interaction was represented by no significant differences in E2 between groups 
on Days 12 to 18 and greater concentration in the IOI group on Days 19 and 20. The 
concentration approached being greater (P < 0.06) in the PCL group on Day 12. The first 
significant increase in E2 concentration occurred between Days 12 and 13 in the IOI group and 
between Days 14 and 15 in the PCL group. Concentration of E2 increased until Day 20 in the 
IOI group, whereas concentration in the PCL group did not differ over Days 15 to 20. 
Concentration of LH had an effect of group and group-by-day interaction after one 
extreme outlier on Day 18 was removed from the IOI group (Fig. 4.1). The effect of group was 
from greater LH concentration averaged over Days 12 to 22 in the IOI group (3.7 ± 0.3 ng/mL) 
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than in the PCL group (1.6 ± 0.1 ng/mL). The group-by-day interaction was represented by no 
differences between groups on Days 12 to 15 and greater concentration of LH in the IOI group 
on Days 16 to 22. The first significant increase occurred between Days 14 and 16 in the IOI 
group and continued to increase until Day 22. In the PCL group, concentration of LH remained 
low and did not differ over Days 12 to 18 and decreased (P < 0.05) from Days 18 to 21. 
Concentration of prolactin had an approaching significant group-by-day interaction 
after two extreme outliers were removed from the IOI group on Days 14 and 15 and one from 
the PCL group on Day 23 (Fig. 4.1). The group-by-day interaction was from no differences 
between groups on Days 12 to 13 and Days 15 to 21 and greater concentration of prolactin in 
the IOI group on Days 14 and 22.  
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Figure 4.1. Mean ± SEM concentrations of progesterone (P4), PGFM, estradiol (E2), LH, and 
prolactin in the IOI group and PCL group. Probabilities for main effects of group (G) and day 
(D) and the interaction (GD) are shown. An asterisk (*) indicates a day with a difference (P < 
0.05) between groups. 
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Figure 4.2. Concentration of progesterone (P4) in 12 individual mares in the IOI group (A, C, 
E, G I, K) and PCL group (B, D, F, H, J, L). Mares are paired between groups according to 
maximal concentration on Days 12 or 13. A pronounced 1-day decrease (a portion of luteolysis) 
is apparent in each IOI mare. A pronounced decrease (apparent initial portion of luteolysis) are 
shown for three mares (B, F, H) and a gradual decrease for three mares (D, J, L) in the PCL 
group; however, concentrations were irregular in one mare (B). Compared to the IOI mares, 
P4 in the PCL mares decreased only about 50%. 
 
Cross-sectional area of CL had significant effects of group and day and a group-by-day 
interaction (Fig. 4.3). The effect of group was from greater CL area averaged over Days 11 to 
19 in the PCL group (4.1 ± 0.1 cm2) than in the IOI group (3.0 ± 0.2 cm2). The group-by-day 
interaction was represented by no differences between groups on Days 11 to 15 and greater 
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area of CL in the PCL group on Days 16 to 19. The first significant decrease occurred between 
Days 13 and 14 in the IOI group and between Days 14 and 15 in the PCL group. Area of CL 
decreased progressively until Day 19 in the IOI group, whereas area of CL did not differ in the 
PCL group over Days 15 to 19 and increased (P < 0.05) between Days 19 to 21.  
Daily percentage of CL with blood-flow signals had significant effects of group, day, 
and a group-by-day interaction (Fig. 4.3). The effect of group represented greater percentage 
of CL with blood-flow signals averaged over Days 11 to 18 in the PCL group (49.0 ± 2.0%) 
than in the IOI group (36.2 ± 3.5 %). The group-by-day interaction was represented by no 
significant differences between groups on Days 11 to 15 and greater percentage of CL with 
blood-flow signals in the PCL group on Days 16 to 18. The first significant decrease in 
percentage of CL with blood-flow signals occurred in both groups between Days 13 and 14. 
Blood-flow signals decreased until Day 18 in the IOI group but did not differ over Days 15 to 
18 in the PCL group. The percentage of CL with blood-flow signals in the PCL group 
approached being greater (P < 0.1) on Day 28 than on Day 15. 
Daily diameter of the largest follicle had a significant effect of day and a group-by-day 
interaction (Fig. 4.3). The group-by-day interaction reflected no differences between groups on 
Days 11 to 15 with a progressively increasing disparity between groups, so that diameter of the 
largest follicle was greater in the IOI group than in the PCL group on Day 21. The growth rate 
of the largest follicle on Days 11 to 21 was greater (P < 0.006) in the IOI group (2.4 mm/day) 
than in the PCL group (1.4 mm/day). In addition, the maximum diameter reached by the largest 
follicle was greater (P < 0.01) in the IOI group (48.6 ± 2.8 mm) than in the PCL group (38.5 ± 
2.4 mm). The diameter of the largest follicle in the PCL group did not differ over Days 22 to 
28.  
Score for endometrial edema had a significant effect of group and day and a group-by-
day interaction (Fig. 4.3). The group effect represented greater endometrial score averaged over 
Days 11 to 22 in the IOI group (2.7 ± 0.1) than in the PCL group (1.6 ± 0.1).  The group-by-
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day interaction was represented by no significant differences between groups on Days 11 to 15 
and greater endometrial score in the IOI group on Days 16 to 22. The first significant increase 
in endometrial score was observed in both groups between Days 12 and 13. Endometrial score 
significantly increased until Day 15 in each group. The scores did not differ over Days 15 to 
22 in the IOI group, whereas in the PCL group the score decreased (P < 0.05) from Days 16 to 
21. 
 
 
 
Figure 4.3. Mean ± SEM for area of CL, percentage of CL with blood-flow signals, diameter 
of the largest follicle, and endometrial score in the IOI group and PCL group. Probabilities for 
main effects of group (G) and day (D) and the interaction (GD) are shown. An asterisk (*) 
indicates a day with a difference (P < 0.05) between groups. 
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4.4. Discussion 
 
Several precautions were taken to allow critical statistical comparisons between mares 
that subsequently did and did not develop apparent idiopathic PCL. In the three years before 
and during the current study, the mares were ≤ 14 y of age and therefore less likely to have the 
reproductive complications of senescence [36–38]. The mares were not bred, precluding the 
effects of early embryonic death on PCL [39]. In addition, uterine complications (e.g., metritis, 
pyometra) were not likely involved in that even small intraluminal fluid collections (indicators 
of metritis [30,40]) were not detected at any time during the three ovulatory seasons. Therefore, 
the PCLs were not attributable to uterine pathology (uteropathic PCL) and the PCLs were 
considered idiopathic [10]. Body condition or health complications were not apparent 
throughout the 3 y. Unique aspects of the study were: (1) exclusion of IOIs and PCLs with 
more than one CL or with the development of a hemorrhagic anovulatory follicle [30] and (2) 
matching of each PCL with an IOI according to the month of ovulation at the beginning of the 
PCL or IOI during what was considered part of the ovulatory season (May to October for these 
mares). Matching of months minimized confounding that may have occurred because of 
seasonal effects on the mare reproductive system [1,41].  
 Concentration of P4 before expected luteolysis was similar between mares with and 
without PCL, as indicated by no difference in P4 concentration between the IOI and PCL 
groups on Days 12 to 14. However, concentration before Day 12 was not available. The mean 
decrease in P4 during luteolysis involved Days 13 to 17 in the IOI group. In the PCL group, 
the mean decrease in P4 concentration discontinued on Day 15 at about 50% of the 
concentration on Day 12 and became constant. The similarity in P4 concentration between IOIs 
and PCLs until Day 14 and the plateau of lesser concentration beginning on Day 15 for PCLs 
seems consistent with reported P4 profiles in individual PCL mares [15]. The constant P4 
concentration in individuals beginning on mean Day 15 in the PCL group in the current study 
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was preceded by either a 1-day abrupt decline or a gradual decline. Although confirmation is 
needed, these results indicated that P4 concentration in some mares with idiopathic PCL may 
begin to decline abruptly as for the beginning of luteolysis, whereas in others the decline may 
be gradual as reported for P4 of an IOI (Days 8 to 14 [42]). Apparently, PCL can begin by an 
initial period of partial luteolysis in some mares and a continuation of the gradual preluteolytic 
decrease in other mares. This is a novel observation in that only the apparent plateau in P4 
concentration was observed previously in individual mares with PCL [15]. 
During the PCL, the area of the CL and percentage of blood-flow signals of the CL 
followed the same pattern as the P4 profile; divergence between IOI and PCL groups occurred 
on Day 15. This observation shows that functional changes in circulating concentration of P4 
relate to structural changes in CL cross-sectional area and vascularity as expected. In this 
regard, the structural changes were determined before P4 concentration was known, thereby 
assuring objectivity.  
 Hypothesis 1 that secretion of PGF2α at the time of expected luteolysis is defective in 
mares with idiopathic PCL was not supported. This was indicated by the similarity (no 
significant differences) in daily PGFM concentration between groups, including a maximum 
concentration on Day 15 in each group. The daily concentrations of PGFM, as for LH and 
prolactin, did not consider the distinct pulses of the hormones that have been demonstrated in 
hourly blood samples [6,27]. The concentrations in daily samples depends on whether a pulse 
was underway when the sample was taken, but even at the nadirs the concentration is greater 
during luteolysis than before luteolysis [7]. It is expected therefore that the daily samples 
provided a useful overview. Results of the current daily samples encourage further study using 
more frequent sampling. A deficiency in PGF2α secretion has been observed in individual 
mares with uteropathic PCL [13]. The comparison of the IOI and PCL groups in the current 
study did not support the apparent supposition [11,17] that idiopathic PCL is attributable to a 
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deficiency in PGF2α secretion.  However, further study with more mares and more frequent 
sampling is needed. 
Hypothesis 2 that E2 concentration before expected luteolysis is greater in mares that 
develop PCL was not supported. Lack of support was from the similar concentration between 
groups on Days 12 to 15 or before divergence in P4 between groups. The main rationale for 
the hypothesis was the report that urinary estrogens are higher on Days 5 to 10 in mares that 
develop PCL [25]. A report on the associations among follicles, luteal function, and plasma E2 
found no difference between the early (Days 2 to 5) and late (1 to 3 days before luteolysis) 
luteal phases in mares that developed PCL [26]. However, although apparently not analyzed or 
commented upon, tabulated data indicates that E2 on Days 2 to 5 may have been greater in a 
group that developed PCL (24.7 ± 1.8 pg/mL) than in a group that did not develop PCL (20.9 
± 0.7 pg/mL) [26]. Whether E2 is involved in the PCL syndrome has not been resolved by 
challenges with E2 administration. Several studies have indicated that exogenous estrogen does 
not alter the life span of the CL in mares [43–45], as it does in other species [1], which would 
be consistent with the conclusion that E2 does not play a role in the stimulation of idiopathic 
PCL. Nevertheless, greater urinary estrogen concentration during the early luteal phase [25] 
and the approaching greater plasma E2 concentration on Day 12 in the PCL group in the current 
study indicate that further study on a role of E2 in PCL development is needed, especially for 
Days 0 to 12. 
An increase in E2 in the IOI group beginning before Day 16 agrees with previous 
findings that plasma E2 begins a progressive increase on Day 13 [46] and that E2 increases 
before the follicle deviation of Days 16 or 17 [47,48]. The divergence in E2 concentrations 
between groups beginning on Day 16 represented increasing concentration in the IOI group but 
not in the PCL group, consistent with a report that E2 did not increase during late diestrus in 
mares with PCL [26]. These findings for E2 apply to mares in which PCL has already been 
established and thereby represent the consequences of persistent P4 concentration rather than 
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for a role of E2 as an etiologic factor. In a study of hourly blood samples, E2 did not begin to 
increase until 5 h after the beginning of luteolysis [6]. Thus, if an increase in E2 is involved in 
PCL development, the increase apparently would be transient and would occur well before 
luteolysis. 
In regard to the characterization of circulating concentration of LH, the beginning of an 
increase in LH on Day 14 in the IOI group and a progressive increase until Day 22 are 
consistent with the reported characteristics of the ovulatory LH surge in mares [49]. The surge 
reaches a peak the day after ovulation and therefore the peak was not expected to be included 
in the current study; ovulation at the end of the IOI occurred on mean Day 22. The LH increase 
during an IOI began 2 days before the end of luteolysis (P4 < 1 ng/mL), similar to previous 
reports [6,48,50]. Reports on LH concentration during PCL are contradictory and are only 
available for individual mares; both high [16] and low [18] concentration of LH have been 
observed. In the current study, absence of an increase in LH in the PCL group involved Days 
12 to 22, contrasting with the LH increase in the IOI group. The low LH concentration in the 
PCL group, however, did not likely contribute to or reflect the initiation of the PCL on Day 15 
in that LH was not lower in the PCL group until Day 16, the day after the mean divergence in 
P4 concentration in the two groups. The maintenance of greater P4 concentration in the PCL 
group may have played a role in the low LH. In this regard, P4 treatment has been shown to 
depress LH concentration during the IOI in mares [51].  
Concentration of prolactin was considered in the current study, despite previous failures 
to find a luteolytic or luteotropic role of prolactin in mares [52]. In addition, a previous study 
did not find an effect of prolactin concentration in association with the development of PCL 
[11]. Concentrations of PGFM, LH, and FSH in addition to P4 were not affected during a 
reported increase in prolactin [52]. A role for prolactin was nevertheless considered in the 
current study because of its role in reproductive seasonality in mares [53,54] and the report that 
pulses of prolactin are in synchrony with pulses of PGFM, apparently representing the 
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stimulation of prolactin by PGF2α [27]. Therefore, if a deficiency of PGF2α had a role in the 
etiology of idiopathic PCL, concentration of prolactin might also have been different. However, 
the current results on a role of prolactin in PCL were inconclusive. That is, the statistical 
interaction of group and day only approached significance from apparent lower concentration 
in the PCL group than in the IOI group on Day 13 and Day 22. In addition, the current study 
and previous reports have not identified an apparent luteotropic factor or mechanism that may 
be involved in the prevention of luteolysis in some PCL mares and the early cessation of 
luteolysis in other PCL mares. Despite the current negative findings, luteotropic involvement 
of prolactin as well as LH in PCL development should be further considered, owing to the 
absence of a firm demonstration that defective secretion of the luteolysin (PGF2α) plays the 
primary role in the development of idiopathic PCL.  
The dominant follicle in the PCL group that corresponds to the preovulatory follicle in 
the IOI group was inhibited. The diameter of the largest follicle began to increase similarly in 
the two groups on Days 11 to 15 but began to diverge between groups on Day 16 and attained 
a lower diameter in the PCL group on Day 21. The slower growth rate and smaller maximal 
diameter of the largest follicle in the PCL group are attributable to the lesser concentration of 
LH in the PCL group. Circulating LH is needed for the continued growth of the largest follicle 
after the beginning of deviation in mares [51]. In the current study divergence in LH between 
groups began within a day after the reported diameter of the largest follicle at deviation (22 to 
25 mm; [47,55]). In a previous study, follicle emergence was delayed in mares that developed 
spontaneous PCL [26]. In contrast, a negative effect on follicles in the current study was 
indicated by slower growth of the largest follicle but not by a delay in day of emergence. 
 Endometrial edema initially increased in both the IOI and PCL groups in synchrony 
with an increase in E2 and the decrease in P4 in each group on Days 12 to 15. After the 
divergence in P4 concentration between groups, endometrial edema began to decrease on Day 
16 in the PCL group in temporal association with P4 persistence and lack of an increase in E2. 
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These results are consistent with the concept that endometrial edema during estrus is a 
consequence of increasing circulating E2 and decreasing P4 [56]. 
 
4.5. Conclusions 
 
An initial decrease in P4 occurred during apparent idiopathic PCL and reached a stable 
concentration on mean Day 15.  The P4 decrease began abruptly in two individuals in the PCL 
group as during luteolysis in the IOI group, but apparent luteolysis was incomplete. The P4 
decrease was gradual in three PCLs. Concentration of P4 began to diverge between the IOI and 
PCL groups on Day 14 and was greater in the PCL group on Days 15 to 22. Although 
concentration of E2 approached being greater (P < 0.06) in the PCL group on Day 12, 
divergence between groups did not begin until Day 16, so that concentration was not greater in 
the IOI group until Days 19 and 20. Concentration of LH remained low in the PCL group and 
was greater in the IOI group on Days 16 to 22. There was no indication that an increase in LH 
could have acted as a luteotropin to account for the discontinuation of a P4 decrease in the PCL 
group. Prolactin concentrations were equivocal in that an interaction between groups only 
approached significance. 
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Abstract 
 
Persistent CL (PCL; n = 10) in mares was studied daily from Day 20 (Day 0 = ovulation) 
to the ending ovulation. In addition, the 10 days before ovulation at the end of a PCL were 
compared with the end of an interovulatory interval (IOI; n = 28) during the same months. 
Concentration of P4, cross-sectional area of CL, and percentage of CL with Doppler signals of 
blood flow during PCLs remained constant from 64 to about 33 days before the end of 
luteolysis and then decreased linearly. Concentration of LH between Day 20 and beginning of 
the ovulatory LH surge increased linearly. A dominant follicle developed on average every 15 
days throughout each PCL. Novel transient P4 depressions were detected with the P4 nadir at 
a day of maximal diameter of a dominant follicle. At the apparent beginning of luteolysis before 
the ending ovulation, P4 concentration in PCLs (5.0 ± 0.5 ng/mL) was less (P < 0.0001) than 
in IOIs (9.3 ± 0.6 ng/mL). Concentration of LH began to increase 2 days before the end of 
luteolysis in each group, but concentration on the day of the ending ovulation in PCLs (3.7 ± 
0.3 ng/mL) was less (P < 0.005) than in IOIs (8.9 ± 1.8 ng/mL). In a separate survey of PCLs 
(n = 23) and IOIs (n = 352), frequency of PCL (6.1%) differed significantly among mares 
indicating repeatability. These original and critical comparisons between PCLs and IOIs should 
provide hypotheses for further study. 
 
 
Keywords: Corpus luteum; Dominant follicle; LH; Persistent CL; Progesterone. 
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5.1. Introduction 
 
In farm animals, including horses, the corpus luteum (CL) forms at the site of ovulation. 
The CL secretes progesterone (P4) which prevents another period of estrus and ovulation until 
after functional and structural CL regression or luteolysis. The control of the CL and the nature 
of luteolysis in mares have been reviewed [1–5]. In mares, luteolysis begins on average at Day 
14 (Day 0 = ovulation) and is completed in 23 h, based on hourly blood sampling [6]. A P4 
concentration decrease to < 1.0 ng/mL is used to define the end of luteolysis [7]. 
A CL that is maintained beyond the expected time of luteolysis in a nonpregnant mare 
is termed persistent CL (PCL) [8]. The condition can affect 8–10% of interovulatory intervals 
(IOIs) during the peak of the ovulatory season and 25% during the transition into the 
anovulatory season [9–11]. The PCL syndrome has been associated with uterine pathology 
(e.g., pyometra) [12] and with embryonic loss after the first luteal response to pregnancy [13]. 
The term uteropathic PCL is appropriate when the condition can be attributed to a uterine 
abnormality or pathology [14]. When the etiology is unknown and cannot be attributed to the 
uterus or to embryonic death, the terms idiopathic PCL [14] and spontaneous PCL [7,15] have 
been used. 
Mares with PCL have a P4 concentration > 1.0 ng/mL for about 60 days (range: 35 to 
95 days) [7]. Uteropathic PCL is attributable to a defect in endometrial secretion of the 
luteolysin prostaglandin F2α (PGF2α) [12]. Idiopathic PCL also has been attributed to 
defective PGF2α secretion, based on concentrations of P4 and PGFM (a metabolite of PGF2α) 
in a few individual mares [11,16].  
Studies on the characteristics of idiopathic PCL have considered concentrations of P4, 
LH, PGFM, or estradiol (E2) in individual mares and have focused on the expected transition 
between the luteal and follicular phases [11,16–18]. Long-term characterization of hormonal 
changes during PCL (e.g., Day 20 to ovulation) have been limited to P4 [7–19]. Detailed 
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descriptions of variations in P4 concentration, ovulation, and estrous behavior are available for 
individuals [7,15,19]. Concentration of P4 in PCL decreases to an intermediate plateau 
beginning on about Day 14 [7]. An abrupt decrease in P4 concentration (luteolysis) occurs after 
the intermediate plateau in PCL mares, whereas a continuing gradual decrease occurs in 
hysterectomized mares [7,20]. After Day 20, mares with PCL appeared to have low 
concentration of LH [15,19], and in one mare LH concentration increased for 9 days before 
luteolysis [19]. Follicular growth occurs during PCL with some of the follicles reaching 
ovulatory size. Ovulation may occur [7,19], but estrous behavior during PCL has not been 
reported [17].  
Consideration has not been given to the long-term characterization of follicular waves 
(e.g., frequency of major waves, maximum diameter of the dominant follicle) and the CL (e.g., 
cross-sectional area, extent of blood flow) during PCL. In the current study, daily 
concentrations of P4, LH, and FSH were determined, but E2 was considered only for selected 
portions of major follicular waves. Characteristics of dominant follicles and luteal dimensions 
and blood flow were included. In addition, normalization to luteolysis or to ovulation at the 
end of a PCL compared to the end of an IOI has not been used for critical retroactive 
comparison of mares with and without PCL. The current study compared mares with and 
without PCL retroactively from the end of luteolysis and from ovulation at the end of an IOI 
or PCL.  
Although the IOI and PCL were compared, the results are considered observational in 
that there was inadequate rationale for developing hypotheses for comparing P4, FSH, LH, and 
E2 concentrations, follicles, and CL between the end of an IOI and the end of a PCL. 
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5.2. Materials and methods 
 
5.2.1. Mares 
 
Mixed breeds of 28 nonlactating mares aged 3 to 18 years and weighing 300 to 600 kg 
were used in the northern temperate zone. The wide range of weight and body conformation 
indicated that individual mares could be described as a horse (riding type) or a pony-horse 
cross. Abnormalities of the reproductive tract were not detected by transrectal ultrasonic 
scanning [21]. The mares had not been bred for at least 3 years. The experiment characterized 
PCL after Day 20 and was done from July 2012 through November 2013. Mares were housed 
in an open shelter and outdoor paddock and were maintained by free access to primarily grass 
hay, trace-mineralized salt, and water. The mares were housed under natural light during 
spring, summer, and fall (March through November) and under artificially extended 
photoperiod during the winter (December through February) as described [3]. All mares 
remained healthy and in good body condition throughout the study. Mares were handled 
according to the United States Department of Agriculture Guide for Care and Use of 
Agricultural Animals in Agricultural Research and Teaching. 
 
5.2.2. Protocol 
 
Mares were examined daily by transrectal ultrasound with a duplex B-mode (gray scale) 
and color-Doppler ultrasound scanner (Aloka SSD 3500; Aloka American, Wallingford, CT, 
USA) equipped with a linear-array 7.5 MHz transducer. The scanner was used for determining 
the day of ovulation, luteal area (cm2) at the maximal cross-sectional plane, endometrial score 
from 1 to 4 (minimal to maximal) as an estimate of the extent of endometrial edema [21,22], 
and percentage of CL with power-Doppler signals for blood flow [23,24]. The percentage of 
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CL with power-Doppler signals of blood flow was estimated from a scan of the entire CL as 
described and validated [25]. Identity of each follicle ≥ 15 mm was maintained from day to day 
[21]. 
Regression of the CL was detected by a decrease in CL area and an associated decrease 
in percentage of CL with blood-flow signals. A cluster analysis indicated that a 20-day length 
of luteal phase (ovulation to P4 < 1.0 ng/mL) best distinguished between a mare with a PCL 
and a mare with an IOI. Criteria for assigning 28 IOIs to the IOI group were: (1) length of luteal 
phase was less than 20 days, (2) the IOI was a control in a previous experiment, (3) a single 
ovulation at the beginning of the IOI, (4) ovulation at the end of the IOI occurred during April 
to October, and (5) daily ultrasound scanning records and blood samples were available from 
Day 12 to ovulation. Criteria for assigning 10 PCLs to the PCL group were: (1) length of luteal 
phase was 20 or more days, (2) a single ovulation occurred at the beginning of the PCL, (3) no 
other ovulations or hemorrhagic anovulatory follicles [3,21] were detected between the 
ovulation at the beginning and end of the PCL, and (4) ovulation after the end of the PCL 
occurred during April to October. The criterion for ovulation at the end of the IOI or PCL 
during April to October was used to minimize confounding from season when data were 
considered retroactively from the end of the luteal phase or from the ending ovulation. 
All of 10 PCLs and 28 IOIs were used for comparing groups retroactively from 4 days 
before the end of luteolysis and from 10 days before ovulation at the end of IOI or PCL. Seven 
of the 10 PCLs with an interval of at least 64 days retroactively from the end of the luteal phase 
were used for long-term characterization of P4 concentration, CL characteristics, and LH 
concentration. Three shorter intervals (CL life span of 22 to 26 days postovulatory) were 
excluded to minimize data distortion from shorter intervals. A dominant follicle of a follicular 
wave in PCLs during the interval from Day 20 to ovulation was defined as a follicle that 
reached 30 mm [26]. A major follicular wave was characterized by a dominant follicle and a 
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minor follicular wave by a largest follicle that did not attain the diameter of a dominant follicle 
[27]. The number of major follicular waves after Day 20 in PCLs was determined.  
Transient P4 depressions were identified by their relationship to a linear regression line 
for each PCL from Day 20 until 2 days before the end of luteolysis. The P4 concentration at 
the nadir of a selected depression was ≥ 3 ng/mL and was below the regression line. The 
maximal concentrations of the descending and ascending portions were above the regression 
line. Prominent transient P4 depressions (n = 16) were selected before locations of follicular 
waves and concentrations of E2 were known. A total of 16 transient P4 depressions were 
identified in the seven PCLs with the longer CL life span. The three PCL mares without a 
detected P4 depression had PCLs of short duration. The nadir of the depression was used as a 
normalization point for diameter of the largest follicle and E2 concentration. Concentrations of 
E2 were available from 4 days before to 4 days after the nadir of the transient P4 depression.  
 
5.2.3. Hormone assays 
 
Blood samples were collected into heparinized vacutainer tubes by venipuncture of a 
jugular vein. Samples were immediately placed in ice water for 10 min, followed by 
centrifugation (2,000 X g for 10 min). The plasma was decanted and stored (–20 ºC) until 
assayed. The assay procedure for each hormone has been validated and described for mare 
plasma in our laboratory as indicated. Plasma samples were assayed for P4 by a solid-phase 
RIA kit containing antibody-coated tubes and 125I-labeled P4 (Coat-A-Count Progesterone, 
Diagnostic Products Corporation, Los Angeles, CA, USA) [28]. The intra- and interassay 
coefficients of variation (CV) and sensitivity for P4 were 5.7%, 8.1%, and 0.02 ng/mL, 
respectively. Plasma concentrations of FSH and LH were determined by RIA [29]. The intra- 
and interassay CV and sensitivity were 9.7%, 12.8%, and 1.8 ng/mL for FSH and 9.6%, 7.9%, 
and 0.2 ng/mL for LH. The concentrations of E2 were measured by a double-antibody RIA kit 
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(Double Antibody Estradiol, Diagnostic Products Corporation) [29]. The intra- and interassay 
CV and sensitivity were 5.9%, 7.1%, and 0.06 pg/mL, respectively. 
 
5.2.4. Statistical analyses  
 
The SAS PROC CLUSTER (version 9.3; SAS Institute Inc., Cary, NC, USA) program 
used the day of the end of luteolysis for dividing the intervals between the beginning and ending 
ovulations into the experimental groups (IOI and PCL). In the PCL group, multiple linear 
regression based on SAS PROC REG were used for long-term (64 days) characterization of 
P4, area and blood-flow signals of CL, and LH normalized for each factor retroactively to the 
day before preovulatory changes appeared to begin near the end of luteolysis. The regressions 
ended 2 days before the end of luteolysis for P4 and area and blood-flow signals of CL and 10 
days before the end for LH. For comparing the IOI and PCL groups normalized to the end of 
luteolysis and to the ending ovulation, data were examined for normality using the Shapiro-
Wilk test. Data that were not normally distributed were resolved by transformation to natural 
logarithms or ranks. The statistical analyses were done by using SAS PROC MIXED. A 
repeated statement was used to account for autocorrelation by modeling the first-order 
autoregressive between sequential measurements. Determination was made of the main effects 
of group and day and the interaction of group by day from 4 days before to 5 days after the end 
of luteolysis and Days –10 to 0 normalized to the ending ovulation. When a significant 
interaction of group by day was found, Student’s unpaired t-tests were used for comparing 
differences between IOI and PCL groups within each day. A probability of P ≤ 0.05 indicated 
that the difference was significant, and a probability of P > 0.05 to ≤ 0.10 indicated that 
significance was approached. Differences that approached significance were included on a 
preliminary basis for potential consideration in further studies. Data are presented as the mean 
± SEM, unless otherwise indicated. 
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5.2.5. Survey 
 
In addition to long-term characterizations of PCL and comparisons of IOI and PCL 
groups in the main experiment, daily ultrasound scanning records from February 2012 to 
November 2013 were surveyed. The length of an IOI and PCL and month of ovulation at the 
beginning and end of the IOI or PCL were recorded. The frequency of PCL in the herd was 
determined. A total of 375 intervals between ovulations (23 PCLs and 352 IOIs) were obtained 
from an average of 21 mares during the 22 months (462 mare/months). The repeatability of 
PCL in individuals was expressed as the percentage of intervals between beginning and ending 
ovulations with formation of a PCL versus an IOI. Body weight, height at the withers, and 
body-mass index [30] were determined. Body-mass index was used to determine if PCL 
frequency in individuals was affected by apparent conformation differences among types of 
mares (horse and pony-horse crosses) and was calculated as body weight (kg)/[height(m)2]. 
The repeatability of PCLs in individual mares and the frequency of the beginning and ending 
ovulation of a PCL during each climatic season were evaluated by chi-square. 
 
5.3. Results 
 
5.3.1. PCL characteristics 
 
The length of intervals from ovulation to the end of luteolysis (luteal phase), from the 
end of luteolysis to ovulation (follicular phase), and from ovulation to ovulation are shown for 
the PCL and IOI groups (Table 5.1). The length of the luteal phase was different between 
groups, but the length of the follicular phase was not. 
The P4 concentration in the PCL group for 64 to 2 days before the end of luteolysis was 
best characterized by a quadratic regression with two segmented linear components from 64 to 
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33 and 32 to 2 days as shown (Fig. 5.1). The linear component for P4 concentration from 64 to 
33 days was constant as indicated by a nonsignificant linear regression and the component from 
32 to 2 days was represented by a linear decrease (P < 0.0001). The decrease in the PCL group 
(0.09 ng/mL per day) from 32 to 2 days was less (P < 0.0001) than the decrease in the IOI 
group (0.74 ng/mL per day) from 6 to 2 days preceding the apparent luteolytic period. Cross-
sectional area of CL was also best characterized by a quadratic regression with two segmented 
linear components. Blood-flow signals in the CL were best characterized by a cubic regression 
with three segmented linear components. Concentration of LH between 64 and 10 days before 
the end of luteolysis in the PCL group increased at a rate of 0.005 ng/mL per day and was best 
characterized by a linear regression; concentration remained low (range of minimal and 
maximal means 0.51 ± 0.11 to 0.99 ± 0.22 ng/mL). 
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Figure 5.1. Mean ± SEM concentration of progesterone (P4), cross-sectional area of CL, and 
percentage of CL with blood-flow signals from 64 to 2 days before the end of luteolysis in 
seven PCLs. Results of multiple regression analyzes for each end point are shown. Linear 
components for each end point are indicated by different symbols for the means. 
 
Table 5.1. Mean ± SEM length of intervals from ovulation to ovulation, luteal phase, and 
follicular phase for interovulatory intervals (IOI) and persistent CL (PCL). 
 IOI group (n = 28) PCL group (n = 10)  
End point (days) Mean Range Mean Range Probability 
Ovulation to ovulation 23.5 ± 2.2 18 to 28 74.0 ± 33.7 28 to 121 P < 0.0001 
      
Luteal phasea 16.2 ± 1.2 14 to 19 67.5 ± 32.4 22 to 113 P < 0.0001 
      
Follicular phaseb   7.3 ± 2.0   3 to 13 6.5 ± 2.6 3 to 11 NS 
      
a Ovulation to end of luteolysis 
b End of luteolysis to ovulation 
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The ovulations at the beginning and end of each PCL occurred in the same ovulatory 
season (April to October), except that one PCL of 83 days duration began in January. The 
characteristics of major follicular waves of PCLs during the interval from Day 20 to ovulation 
are shown (Table 5.2). A continuous sequence of major waves (maximum diameter of 
dominant follicle, ≥ 30 mm) occurred throughout all PCLs, except that two of the total of 51 
waves were minor waves (maximum diameter of dominant follicle, 25 and 28 mm). In the PCL 
that began in January, sequential major follicular waves occurred throughout the PCL, 
including waves that occurred in January and February. An illustration of the sequence of major 
waves is shown for two of the longer intervals (101 and 73 days) from Day 20 to ovulation 
(Fig. 5.2).  
 
Table 5.2. Mean ± SEM characteristics of major follicular waves during 10 PCLs from Day 
20 to ovulation. 
End point Mean Range 
No. of major waves/PCL    4.9 ± 0.8    1 to 8 
   
Length from Day 20 to ovulation (days) 54 ± 10.7    8 to 101 
   
Intervals between maximum diameters (days)   
Anovulatory to anovulatory wave 15.2 ± 1.4a 7 to 21 
Last anovulatory to ovulatory wave 
 
10.7 ± 2.0b 6 to 19 
Maximum diameter (mm)   
Anovulatory waves 43.6 ± 1.7 32.1 to 55.6 
Ovulatory waves 
 
46.6 ± 1.9 38.5 to 59.5 
 
ab Means for the interval between maximal diameters for anovulatory to anovulatory 
versus last anovulatory and ovulatory follicular waves are different (P < 0.04). 
 
132 
 
 
Figure 5.2. Individual profiles of dominant follicles of major follicular waves for two mares 
with PCL. The interval between ovulations was 93 and 121 days for the two mares, 
respectively, and the duration of the luteal phase was 89 and 113 days. DF = dominant follicle; 
OV = ovulation; POF = preovulatory follicle. 
 
5.3.2. Transient depressions in P4 
 
Examples of transient P4 depressions during a PCL are shown (Fig. 5.3). A transient 
P4 depression occurred 2.1 ± 0.4 times (range 1 to 4) during the persistent concentrations of 
P4 in PCLs and was not observed during IOIs. The descending and ascending portions of the 
16 transient P4 depressions consisted of a mean of 6 and 7 days, respectively (Fig. 5.4). The 
nadirs had a mean P4 concentration of 5.7 ± 0.4 ng/mL and were located 95 to 25 days before 
the end of luteolysis. The nadir occurred at the mean maximal diameter of a dominant follicle 
when the diameter was 39.2 ± 1.6 mm. A depression did not occur during many (24/41, 58.5%) 
of the major follicular waves. The day effect for E2 when normalized to the nadir of the 
transient P4 depression was not significant. On a preliminary basis, an increase in E2 
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concentration approached significance (P < 0.08) from 4 to 1 days before the nadir, and 
decreased (P < 0.03) from 1 day before to 2 days after the nadir (Fig. 5.4). The concentrations 
of LH and FSH did not change significantly during a transient P4 depression, although an 
increase in FSH between 5 days before the nadir and the day of the nadir approached 
significance (P < 0.10; not shown). 
 
 
 
 
 
Figure 5.3. Profile of concentration of progesterone (P4) for a mare with PCL. The P4 linear 
regression was used as an aid for locating P4 depressions. The location of the nadirs of two 
transient P4 depressions are indicated by the arrow heads on the day scale. 
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Figure 5.4. Mean ± SEM concentration of progesterone (P4; n = 16), diameter of the dominant 
follicle (n = 16), and concentration of estradiol (E2; n = 7) normalized to the nadir of a transient 
depression in P4 concentration during a PCL.  Probabilities for main effect of day (D) that were 
significant are shown. The day effect for E2 was not significant, but on a preliminary basis an 
asterisk (*) indicates days with a difference (P < 0.05) between days, and a hash mark (#) 
indicates days with an approaching difference (P < 0.08). 
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5.3.3. Normalization to end of luteolysis and to ovulation 
 
Concentrations of P4, LH, and FSH for 4 days before to 5 days after the end of luteolysis 
are shown (Fig. 5.5). Concentration of P4 had an effect of group and day and a group-by-day 
interaction. The effect of group was represented by a lower mean P4 concentration in the PCL 
group (2.2 ± 0.3 ng/mL) than in the IOI group (3.9 ± 0.3 ng/mL). The group-by-day interaction 
resulted primarily from greater (P < 0.05) concentration of P4 in the IOI group 4 to 2 days 
before the end of luteolysis and no differences between groups on the other days. A decrease 
(P < 0.05) in P4 concentration, apparently representing the day at the beginning of luteolysis, 
occurred 2 days before the end of luteolysis in each group.  
Concentration of LH had a main effect of day and a group-by-day interaction (Fig. 5.5). 
The group-by-day interaction resulted primarily from less (P < 0.05) LH concentration in the 
PCL group during each day before the end of luteolysis and 1, 4, and 5 days after the end of 
luteolysis. An increase in concentration of LH began 2 days before the end of luteolysis in each 
group. A group effect approached significance and on a preliminary basis represented greater 
LH concentration averaged over 4 days before to 5 days after the end of luteolysis in the IOI 
group (2.4 ± 0.2 ng/mL) than in the PCL group (1.5 ± 0.1 ng/mL). Concentration of FSH had 
a main effect of day and a group-by-day interaction (Fig. 5.5). The group-by-day interaction 
was represented primarily by less (P < 0.02) concentration in the PCL group 4 days before the 
end of luteolysis. 
After normalized retroactively from ovulation, concentration of LH was significantly 
less in the PCL group (1.9 ± 0.1 ng/mL) than in the IOI group (3.3 ± 0.3 ng/mL), as indicated 
by a group effect (Fig. 5.6). An effect of day on LH concentration resulted from an increase 
that began on Day –6 averaged over the two groups. Concentration of FSH had a main effect 
of day and an interaction that approached significance. When each group was analyzed 
separately, the difference among days was significant for the IOI group but not for the PCL 
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group. The diameter of the preovulatory follicle normalized to ovulation had significant main 
effects of group and day (Fig. 5.6). The effect of group was from greater diameter of the 
preovulatory follicle in the PCL group (38.2 ± 1.0 mm) than in IOI group (32.7 ± 0.6 mm). An 
effect of day represented increases after Day –10 averaged over groups. The length of the 
interval from a 20-mm future dominant follicle to ovulation was longer (P < 0.0006) in the 
PCL group (11.8 ± 1.2 days) than in the IOI group (8.9 ± 0.3 days). 
 
Figure 5.5. Mean ± SEM concentration of progesterone (P4; n = 28 IOIs, 10 PCLs), LH (n = 
9 IOIs, 6 PCLs), and FSH (n = 9 IOIs, 6 PCLs) from 4 days before to 5 days after the end of 
luteolysis. Probabilities for main effects of group (G) and day (D) and the interaction (GD) that 
were significant or approached significance are shown. An asterisk (*) indicates a day with a 
difference (P < 0.05) between groups and a hash mark (#) indicates a day with an approaching 
difference (P < 0.07). 
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Figure 5.6. Mean ± SEM concentration of LH (n = 9 IOIs, 6 PCLs) and diameter of the 
preovulatory follicle (n = 28 IOIs, 6 PCLs) for 10 days before ovulation. Probabilities for main 
effects of group (G) and day (D) that were significant are shown. An asterisk (*) indicates a 
day with a difference (P < 0.05) between groups. 
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5.3.4. Survey 
 
The frequency of PCL was 6.1% (23/375) of the intervals between ovulations. The 
development of PCL in the 28 mares during July to November of the following year had 
measurable repeatability within mares. Repeatability was indicated by a difference (P < 0.0001) 
in frequency ranging from 0 to 75% among mares. The percentage of PCLs for individuals 
were 75% (one mare), 30 to 31% (three mares), 5 to 12% (five mares) and 0% (19 mares). The 
mare with the 75% frequency had a PCL during three of four intervals between ovulations. 
There were no significant effects of age, body weight, height, or body-mass index on the 
frequency of development of PCL (Table 5.3). Also, there was no difference in the proportion 
of horses and pony-horse crosses that developed PCL. The probability for development of a 
PCL based on the beginning ovulation was not different among climatic seasons, even when 
combinations of two seasons were used (spring and summer compared to fall and winter). 
However the proportion of PCLs ending in each season differed (P < 0.03); the frequency of 
PCLs ending during spring, summer, fall, and winter in relation to the total number of intervals 
between ovulations was 3/120a (2.5%), 7/134a (4.9%), 5/97a (5.2%), and 4/20b (20%), 
respectively; frequencies with different superscript letters are different (P < 0.05). 
Reproductive events other than the single ovulation at the beginning of the PCL 
occurred in seven of the 23 PCLs as shown (Table 5.4). Profiles of P4 concentration, CL area, 
CL blood-flow, and diameter of the dominant follicles for a mare that ovulated on Day 45 
despite a P4 concentration of 6.7 ng/mL during the PCL are shown (Fig. 5.7). The first major 
anovulatory wave of a PCL that corresponded to the ovulatory wave of an IOI was followed 
by a second ovulatory wave with ovulation on Day 45. A 14.1 ng/mL increase in P4 
concentration occurred after the second ovulation, and concentration remained at 6.6 to 20.7 
ng/mL until the apparent beginning of luteolysis.  
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Table 5.3. Mean ± SEM for mare characteristics in IOI and PCLa. Survey. 
 IOI group (n = 19) PCL group (n = 9) 
End point Mean Range Mean Range 
Age (y)  9.2 ± 0.9 3 to 18     9.1 ± 1.0 4 to 14 
     
Body weight (kg) 464.5 ± 18.2 340.2 to 594.0  441.5 ± 21.4 356.1 to 549.8 
     
Height (m)    1.4 ± 0.02 1.2 to 1.5       1.4 ± 0.02 1.3 to 1.5 
     
Body-mass index 235.6 ± 6.4 185.6 to 273.9  223.0 ± 9.1 202.5 to 292.2 
     
a Differences between groups were not significant and did not approach significance for any 
end point. 
 
 
Table 5.4. Reproductive events other than the ovulation at the beginning of a PCL in seven (A 
to G) of the 23 individual PCLs. Survey. 
 
PCL Events 
A Ovulation on Day 45 when P4 was 6.7 ng/mL (Fig. 5.7) 
  
B, C Hemorrhagic anovulatory follicle on Day 23 or 26 
  
D Resurgence of CL area (1.7 to 3.3 cm2) from Days 18 to 20 
  
E Resurgence of CL area (1.9 to 3.3 cm2) from Days 21 to 23 
and ovulation on Day 23 
  
F,G Double ovulation at beginning of PCL 
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Figure 5.7. Profiles of concentration of progesterone (P4), cross-sectional area of CL, blood-
flow signals of CL, and diameter of dominant follicles for an individual mare with an ovulation 
during the PCL on Day 45. DF = dominant follicle; OV = ovulation; POF = preovulatory 
follicle. 
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5.4. Discussion 
 
There are many reports that focus on PCL characteristics in individual mares (reviews: 
[1,3,9,14,15,31,32]). The current study provides novel information on long-term hormone 
concentrations and follicle and CL dynamics during PCL. In addition, normalization to the end 
of luteolysis for comparison between IOIs and PCLs was done for the first time. The PCLs 
were not attributable to uterine pathology, including the small intraluminal fluid collections of 
metritis [22,33]. Mares were not bred before the study, thereby excluding early embryonic 
death as an etiologic factor [13]. Therefore, the PCLs were considered to be idiopathic [14]. 
Body condition or health complications were not apparent throughout the study. In addition, 
PCLs with more than one CL or with the development of a hemorrhagic anovulatory follicle 
were excluded to allow critical statistical comparisons between groups preceding the ovulation 
at the end of a PCL versus the ovulation at the end of an IOI. Only IOIs and PCLs with an 
ending ovulation during April to October were used. Assigning the beginning and ending 
ovulations of PCLs to one of the four climate seasons minimized confounding that may occur, 
considering that mare reproductive mechanisms are profoundly influenced by season [3,34]. 
Based on a cluster analysis, a PCL was defined as one that had ≥ 20-day interval from ovulation 
to the end of luteolysis. The interval from ovulation to ovulation in the IOI group ranged from 
18 to 28 days and in the PCL group ranged from 28 to 121 days; the common 28-day interval 
was attributable to a shorter follicular phase in the PCL than in the IOI. 
 
5.4.1. PCL characteristics 
 
The concentration of P4 for 64 days before the end of luteolysis during a PCL seems 
compatible with reported P4 profiles for individual PCLs [7]. The current study further 
indicated that the concentration was constant during the first half of the 64 days before the end 
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of luteolysis and then gradually decreased. Concentration of P4 during an IOI is characterized 
by an increase after ovulation until about Day 8 followed by a gradual decrease (preluteolytic 
period) until the abrupt decrease at the beginning of luteolysis [35]. The mechanism for the 
long-term P4 decrease in a PCL may be similar to the mechanism responsible for the P4 
decrease before luteolysis during an IOI. The P4 decrease before luteolysis may represent the 
waning of the positive effects of a luteotropin. In this regard, treatment with pituitary antiserum 
[36], gonadotropins [37], gonadotropin releasing hormone [38], and in vitro culturing of luteal 
cells [37] indicate that the equine CL requires circulating gonadotropins with luteotropic 
activity throughout diestrus and the corresponding days of pregnancy. Receptors for LH have 
been described for equine luteal cells [39,40]. As LH concentrations decline to basal 
concentrations, the number of LH receptors increases and could have accounted for a 
luteotropic effect of low concentrations of LH during the gradual decline in P4 in PCL, even 
though the low LH concentration was slightly increasing. The rate of P4 decrease preceding 
luteolysis at the end of a PCL was slower than during the few days preceding luteolysis in an 
IOI, suggesting the presence of a more robust P4-decreasing mechanism preceding luteolysis 
in an IOI than during the ending portion of a PCL. Further study is needed to determine the 
mechanism for the long-term P4 decline.  
Concentration of LH during PCL gradually increased but was low (e.g., maximal mean, 
0.99 ng/mL), compared to the reported peak of the ovulatory LH surge (e.g., 12 ng/mL) [41] 
for the same assay system. The slight and prolonged LH increase occurred during the decrease 
in P4 concentration. In this regard, treatment with P4 depresses circulating LH concentration 
[42]. Therefore, the continuation of P4 concentration during PCL may account for the 
associated low LH. In this regard, the gradual decrease in P4 was accompanied by a gradual 
increase in LH. 
Changes in P4 concentration during an IOI are related to luteal structural changes that 
follow a similar pattern [35]. During PCL in the current study, the CL cross-sectional area and 
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percentage of CL with blood-flow signals were similar to the P4 profile of PCLs, demonstrating 
the relationship between structural and functional changes. In this regard, the structural 
characteristics were determined before P4 concentrations were known, assuring objectivity. 
Major follicular waves were observed throughout the PCL in the current study, with the 
exception that two waves in one PCL were minor waves by definition. The major waves 
occurred even in January and February, which are considered to be part of the anovulatory 
season; however, only one PCL was involved. To our knowledge, the sequence of major 
follicular waves throughout a PCL has not been described previously. However, the waves 
seem compatible with previously observed follicular activity [19,43]. The maximal diameter 
reached by an anovulatory wave was similar to the maximal diameter of the ovulatory wave 
and seems consistent with a previous observation [19].  
 
5.4.2. Transient depressions in P4 
 
The demonstration of transient depressions in P4 during the long-term phase of a PCL 
and the apparent association between a depression in P4 and the dominant follicle of a major 
wave are novel findings, requiring independent confirmation. Each of the 1 to 4 transient 
depressions in P4 between Day 20 and the end of the PCL was associated with a major follicular 
wave. Not all major follicular waves had a concomitant transient P4 depression; mean number 
of P4 transient depressions per PCL was about half of the mean number of dominant follicles 
or major follicular waves per PCL. Temporal associations between the P4 depressions and 
other hormones and factors were not well established. On a preliminary basis, the decreasing 
portion of a depression occurred during an increase in mean diameter of the dominant follicle, 
so that the maximum diameter occurred at the P4 nadir. In addition, E2 and FSH tentatively 
increased (approached significance) during the P4 decrease and diameter increase. A change 
in LH concentration was not detected during the decreasing P4 concentration and increasing 
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diameter of the dominant follicle. Further studies are needed to determine the origin of the 
apparent transient depressions in P4 concentration during a PCL. 
 
5.4.3. Normalization to end of luteolysis and ovulation 
 
The observation that concentration of P4 immediately before luteolysis was less in the 
PCL group than in the IOI group is consistent with the prolonged gradual decrease in P4 
concentration in the PCL group compared to the IOI group. The reason for a less-prominent 
increase in LH during the ovulatory LH surge in the PCL group than in the IOI group is not 
known, but may be related to the prolonged P4 decrease. The effects of a long-term exposure 
of P4 on LH concentration during an eventual ovulatory surge in mares has not been described. 
In this regard, elevated endogenous P4 concentrations result in reduced frequency of episodic 
GnRH release and lower circulating concentrations of LH without altering the FSH output [44]. 
The exposure of the hypothalamus to P4 concentrations during a long period may lead to a 
refractory period in which GnRH secretion is reduced. Further study will be needed on the 
potential impacts of long term P4 feedback on hypothalamic function in mares.   
 The approximately 3-day longer interval from a 20-mm largest follicle to ovulation in 
the PCL group than in the IOI group indicates a slower growth rate in that the preovulatory 
diameters (Days –2 and –1) were not different between groups. The longer interval accounts 
for the greater diameter of the largest follicle in the PCL group on Days –10 to –2. The slower 
development of the follicle in the PCL group is attributable initially to the lower concentrations 
of FSH and later to the lower concentrations of LH. Early development of both major and minor 
follicular waves are associated with an FSH surge that reaches a peak when the future dominant 
follicle is about 15 mm [45]. After the follicle reaches about 28 mm, LH becomes especially 
important for continued growth of the dominant follicle [46]. 
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5.4.4. Survey 
 
Reports on the incidence of the PCL in different climatic seasons seem contradictory. 
The PCL has been reported to be more frequent in the summer [43,47] and in the fall [15]. In 
the present study, no differences were found in the frequency of the initiation of PCL among 
seasons. However, more PCLs ended in winter than in the other seasons. The difference among 
seasons for the ending of a PCL may be related to the seasonality of mare reproductive 
mechanisms. Most of the mares stopped ovulating during winter, which may have accounted 
for fewer PCLs ending in the spring. In addition, the variation in length of PCL among mares 
likely led to PCLs beginning and ending in the same season or in a different season.  
The diagnosis of PCL when based primarily on P4 concentration is complicated by the 
occurrence of other reproductive events after the beginning ovulation that may or may not have 
contributed to the prolonged delay before luteolysis at the end of the PCL. Such complications 
have been reported [7,19] and have been reviewed [14]. These complicating events include 
ovulation toward the end of diestrus when the new CL is not responsive to the luteolysin 
(PGF2α). In the current study, complicating events occurred during 7 of 23 PCLs and included 
ovulations, hemorrhagic anovulatory follicles, and resurgence in cross-sectional CL area and 
percentage of CL blood flow. Apparently, hemorrhagic anovulatory follicles during a PCL 
have not been previously reported. 
Body-mass index, body weight, height, age, and mare type (riding horses, pony-horse 
crosses) did not have an effect on the frequency of PCL in the current study. However, the 
number of mares with PCLs and IOIs may have been too few to detect differences in PCL 
frequencies. Apparently, PCL is rare in ponies. A PCL was not detected during an extensive 
study with daily monitoring of 14 ponies (mean body weight, 284 kg) for one year [48]. In 
contrast, PCL has been reported to be as common as 25% of estrous cycles in horse mares 
[9,15]. The current demonstration that PCL has measurable repeatability among mares is 
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compatible with previous descriptions for individual mares [7]. Repeatability can be utilized in 
studying the etiologic factors involved in PCLs that are now considered to be idiopathic. 
 
5.5. Conclusions 
 
Concentrations of P4 in 10 mares with PCL remained constant from 64 to 33 days 
before the end of luteolysis and then gradually decreased until the beginning of luteolysis. 
Cross-sectional area of CL and percentage of CL with blood-flow signals followed 
approximately similar profiles as for the changes in P4 concentrations. Major follicular waves 
occurred throughout the PCL at an interval of about 15 days between maximal diameters of 
dominant follicles in adjacent waves. The maximal diameter reached by the dominant follicle 
was similar between anovulatory waves and the terminal ovulatory wave. A novel transient 
depression in P4 concentration was observed in association with about 50% of the major 
follicular waves. In a comparison between 10 PCLs and 28 IOIs during the 10 days before the 
ending ovulation, diameter of the preovulatory follicle was greater in PCLs than in IOIs. 
Concentration of P4 before the apparent beginning of luteolysis in PCLs was 45.8% below the 
concentration in IOIs. During the follicular phase at the end of a PCL, concentration of LH and 
FSH was less prominent than at the end of an IOI. The concentration of LH in the ovulatory 
surge on the day of ovulation in PCLs was 58.5% below the concentration in IOIs.  In a separate 
survey, a PCL occurred in 6.1% of the intervals between ovulations (23 PCLs and 352 IOIs), 
and the frequency of PCL was different among individual mares. 
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6. Discussion and conclusion 
 
There were several objectives during this research. The first objective was to determine 
the role of OT during luteolysis in mares, testing the hypothesis that luteolysis can be induced 
through the administration of OT. It was previously sugested that OT is the hormone 
responsible for transition from preluteolysis to luteolysis in mares, since a small preluteolytic 
PGFM pulse does not initiate luteolysis, but when a similar PGF2α pulse is assotiated with OT 
luteolysis begins [57]. However, in mares the role of OT in the regulation of uterine PGF2α 
secretion and P4 reduction during luteolysis has not been determined [72]. In the first set of 
studies, the effect of exogenous OT on PGFM and P4 concentrations in mares was evaluated. 
In a first approach, a dose and method of OT administration was developed that would stimulate 
a PGFM pulse that was similar to a natural pulse during luteolysis. Constant infusion of a 
specific dose of OT during 2 h stimulated a pulse of PGFM that was similar to reported [52,63] 
spontaneous pulses during and immediately after luteolysis. In contrast to the response to OT 
infusion, bolus treatment in various doses induced a relatively short burst of PGFM that did 
not resemble a natural pulse. The burst reached maximum in 4 min compared to an ascending 
portion of a natural pulse of 2 to 3 h [52,63]. In adition, OT induction of a simulated PGFM 
pulse stimulated a decrease in P4. These results indicated that OT is an intermediary for 
secretion of PGF2α in mares, as previously shown for ruminants [73]. The current results 
apparently represent the first firm demonstration of the luteolytic effect of OT in mares. The 
current successful demonstration is attributable to the infusion of physiologically compatible 
concentrations of exogenous OT, so that the resulting PGFM pulse was similar to a natural 
pulse during luteolysis. The induced decrease in P4 on Day 13 was not associated with a 
reduced length of the IOI, which is attributable to the reported necessity of multiple pulses of 
PGF2α for a continued decrease in P4 or complete luteolysis in mares [56]. In this study, it was 
not possible to seperatly evalute the effects of OT and PGF2α; therefore, the initiation of 
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luteolitic mechanism can only be attributed to the action of both hormones. Future studies 
should attempt to evaluate the role of OT during luteolysis while removing the effect of PGF2α. 
Furthermore, the evaluation of the role of PGF2α while removing the effect of OT should also 
be tested. If such studies are possible, this should provide valuable information on the role of 
each particular hormone during luteolysis and to the knowlegde of the luteolic mechanism. 
The mechanism involved in spontaneous or idiopathic prolonged luteal activity is not 
well understood, but impaired PGF2α secretion has been suspected [1,68,69,71]. In a second 
study, a cyclooxygenase inhibitor (FM) was administered at the time of expected luteolysis to 
induce the formation of the PCL. Treatment with FM during the expected luteolytic period 
(Days 14 to 16) in mares inhibited the secretion of PGF2α, as indicated by a metabolite (PGFM) 
and as previously reported for cattle [74] and sheep [75]. Inhibition of PGF2α synthesis 
interfered with luteolysis. Greater P4 concentration in the FM group during Days 15 to 18 and 
longer intervals from ovulation to the beginning and to the end of luteolysis were observed in 
the FM group. The beginning of luteolysis and the end of luteolysis were each delayed 
approximately 1 day by FM treatment. The similar 1-day delay in the beginning and in the end 
of luteolysis and the approximately parallel decrease in P4 between groups indicated that the 
effect of the reduction in PGF2α was exerted at the beginning of luteolysis, rather than during 
the later portion of luteolysis. These results were unexpected but suggest that PGF2α exerts its 
major effect at the initiation of luteolysis. This is apparently the first demonstration in mares 
that inhibiting PGF2α interferes with luteolysis. Inhibition of PGF2α at the expected time of 
luteolysis may also lead to prolonged luteal activity. However; precaution should be taken 
when making the conclusion that the absence of PGF2α is in the origin of the PCL syndrome 
since only two mares in the FM group met the definition of prolonged luteal activity on the 
basis of statistical outliers involving the luteal phase. In addition, the observed length of luteal 
activity (21 and 36 days) was shorter compared with the reported values of a minimum of 30 
days [1,69].  
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In a third and fourth studies, the characterization and description of the hormonal changes 
in the development of an idiopathic persistent corpus luteum (PCL) (during the time of 
expected luteolysis that failed to occur) and during the maintenance of the idiopathic PCL were 
performed. Concentration of P4 before expected luteolysis was similar between mares with and 
without PCL. In the PCL group, the mean decrease in P4 concentration discontinued on Day 
15 and became constant compared to a continuous decrease between Days 13 and 17 in IOI 
mares. The similarity in P4 concentration between IOIs and PCLs until Day 14 and the plateau 
of lesser concentration beginning on Day 15 for PCLs seems consistent with reported P4 
profiles in individual PCL mares [69]. In adition, the results indicated that P4 concentration in 
some mares with idiopathic PCL may begin to decline abruptly as for the beginning of 
luteolysis, whereas in others the decline may be gradual as reported for P4 of an IOI (Days 8 
to 14 [46]). In this study, there was no indication that secretion of PGF2α at the time of expected 
luteolysis is defective in mares with idiopathic PCL. This was indicated by the similarity in 
daily PGFM concentration between groups, including a maximum concentration on Day 15 in 
each group. The comparison of the IOI and PCL groups in the current study did not support the 
apparent supposition [1,76] that idiopathic PCL is attributable to a deficiency in PGF2α 
secretion.  However, further studies with more mares and more frequent sampling are needed. 
During the maintenance of the PCL, the concentration of P4 was constant during the first 
half of the 64 days before the end of luteolysis and then gradually decreased, which is 
compatible with reported P4 profiles for individual PCLs [69]. The mechanism for the long-
term P4 decrease in a PCL may be similar to the mechanism responsible for the P4 decrease 
before luteolysis during an IOI. Concentration of LH during PCL gradually increased but was 
low, compared to the reported peak of the ovulatory LH surge  [35]. The slight and prolonged 
LH increase occurred during the decrease in P4 concentration. During the study, major 
follicular waves were observed throughout the PCL. Apparently, the sequence of major 
follicular waves throughout a PCL has not been described previously. However, the waves 
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seem compatible with previously observed follicular activity [77,78]. The maximal diameter 
reached by an anovulatory wave was similar to the maximal diameter of the ovulatory wave 
and seems consistent with a previous observation [78]. The demonstration of transient 
depressions in P4 during the long-term phase of a PCL and the apparent association between a 
depression in P4 and the dominant follicle of a major wave are novel findings. Each of the 
transient depressions in P4 was associated with a major follicular wave, but not all the waves 
were assotiated with a transient depression. Concentration of P4 before the apparent beginning 
of luteolysis in PCLs was 45.8% below the concentration in IOIs. During the follicular phase 
at the end of a PCL, concentrations of LH and FSH were less prominent than at the end of an 
IOI. The concentration of LH in the ovulatory surge on the day of ovulation in PCLs was 58.5% 
below the concentration in IOIs.  The reason for a less-prominent increase in LH during the 
ovulatory LH surge in the PCL group than in the IOI group is not known, but may be related 
to the prolonged P4 decrease. In a separate survey, a PCL occurred in 6.1% of the intervals 
between ovulations (23 PCLs and 352 IOIs), and the frequency of PCL was different among 
individual mares. However, no differences were found in the frequency of the initiation of PCL 
among seasons. 
Unfortunatly, it was not possible in the present studies to clearly identify the mechanism 
leading to the formation of idiopatic PCL in mares. However, a deficiency in PGF2α secretion 
involved in the formation of idiopatic PCL was not supported. More studies with more frequent 
samplig during the expected time of luteolysis are nedded to study hormones with a pulsatile 
secretion. A luteotropic action of LH in the CL has been questionable in runimants; however, 
in mares the role of LH during luteolysis, and particularly, during the devolepment of idiopatic 
PCL has not been studied and should be taken into account in future studies.      
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1 The references refer to the Literature review and general Discussion and conclusion. 
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